Edgar Filing: AKORN INC

Large accelerated filer þ

Accelerated filer o

Non-accelerated filer o (Do not check if a smaller reporting company)

Smaller reporting company o

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Document

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q



þ	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

	FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2018

o	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM ____________ TO ____________

COMMISSION FILE NUMBER: 001-32360

AKORN, INC.

(Exact Name of Registrant as Specified in its Charter)



LOUISIANA	72-0717400
(State or Other Jurisdiction of	(I.R.S. Employer
Incorporation or Organization)	Identification No.)

1925 W. Field Court, Suite 300
Lake Forest, Illinois	60045
(Address of Principal Executive Offices)	(Zip Code)

(847) 279-6100

(Registrant’s telephone number, including area code)

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.



Yes	þ	No	o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).



Yes	þ	No	o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).



Yes	o	No	þ

[1]

At July 26, 2018, there were 125,451,174 shares of common stock, no par value, outstanding.

[2]




	Page
PART I. FINANCIAL INFORMATION
ITEM 1. Financial Statements (unaudited).
Condensed Consolidated Balance Sheets - June 30, 2018 and December 31, 2017	4
Condensed Consolidated Statements of Comprehensive (Loss) Income - Three and six months ended June 30, 2018 and 2017	5
Condensed Consolidated Statement of Shareholders’ Equity - Six months ended June 30, 2018	6
Condensed Consolidated Statements of Cash Flows - Six months ended June 30, 2018 and 2017	7
Notes to Condensed Consolidated Financial Statements	8
ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.	32
ITEM 3. Quantitative and Qualitative Disclosures About Market Risk.	41
ITEM 4. Controls and Procedures.	41
PART II. OTHER INFORMATION
ITEM 1. Legal Proceedings.	42
ITEM 1A. Risk Factors.	42
ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds.	43
ITEM 3. Defaults Upon Senior Securities.	43
ITEM 4. Mine Safety Disclosures.	43
ITEM 5. Other Information.	43
ITEM 6. Exhibits.	43

SIGNATURES

EXHIBIT INDEX

[3]

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements.

Certain prior-period amounts have been reclassified to conform to current-period presentation including cost of sales, selling, general and administrative expenses and other non-operating income (expense), net on the condensed consolidated statements of comprehensive (loss) income and condensed consolidated statements of cash flows.

AKORN, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In Thousands, Except Share Data)



	June 30, 2018 (Unaudited)			December 31, 2017
ASSETS
CURRENT ASSETS
Cash and cash equivalents	$	296,782		$	368,119
Trade accounts receivable, net	187,318			141,383
Inventories, net	191,041			183,568
Prepaid expenses and other current assets	27,613			37,081
TOTAL CURRENT ASSETS	702,754			730,151
PROPERTY, PLANT AND EQUIPMENT, NET	328,909			313,418
OTHER LONG-TERM ASSETS
Goodwill	284,115			285,310
Intangible assets, net	459,812			569,484
Deferred tax assets	6,319			6,521
Other non-current assets	4,647			4,627
TOTAL OTHER LONG-TERM ASSETS	754,893			865,942
TOTAL ASSETS	$	1,786,556		$	1,909,511
LIABILITIES AND SHAREHOLDERS’ EQUITY
CURRENT LIABILITIES
Trade accounts payable	$	50,663		$	51,976
Purchase consideration payable	201			3,901
Income taxes payable	6,792			15,775
Accrued royalties	6,627			5,902
Accrued compensation	17,239			12,286
Accrued administrative fees	35,763			38,598
Accrued expenses and other liabilities	60,946			42,651
TOTAL CURRENT LIABILITIES	178,231			171,089
LONG-TERM LIABILITIES:
Long-term debt (net of non-current deferred financing costs)	817,803			815,195
Deferred tax liability	19,929			43,404
Other long-term liabilities	48,758			48,578
TOTAL LONG-TERM LIABILITIES	886,490			907,177
TOTAL LIABILITIES	1,064,721			1,078,266
SHAREHOLDERS’ EQUITY
Common stock, no par value – 150,000,000 shares authorized; 125,404,158 and 125,090,522 shares issued and outstanding at June 30, 2018 and December 31, 2017, respectively	564,988			550,472
Retained earnings	178,010			294,741
Accumulated other comprehensive loss	(21,163		)	(13,968		)
TOTAL SHAREHOLDERS’ EQUITY	721,835			831,245
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$	1,786,556		$	1,909,511

See notes to condensed consolidated financial statements.

[4]

AKORN, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME

(In Thousands, Except Per Share Data)

(Unaudited)



	Three Months Ended June 30,						Six Months Ended June 30,
	2018			2017			2018			2017
Revenues, net	$	190,944		$	199,140		$	375,007		$	452,560
Cost of sales (exclusive of amortization of intangibles, included within operating expenses below)	109,665			96,371			211,500			201,022
GROSS PROFIT	81,279			102,769			163,507			251,538

Selling, general and administrative expenses	83,694			53,981			146,677			101,564
Acquisition-related costs	64			76			75			87
Research and development expenses	74,271			15,876			105,238			27,167
Amortization of intangibles	13,182			15,504			26,372			30,975
Impairment of intangible assets	1,634			3,058			2,126			3,058
TOTAL OPERATING EXPENSES	172,845			88,495			280,488			162,851

OPERATING (LOSS) INCOME	(91,566		)	14,274			(116,981		)	88,687
Amortization of deferred financing costs	(1,304		)	(1,304		)	(2,608		)	(2,608		)
Interest expense, net	(11,062		)	(9,380		)	(20,640		)	(18,946		)
Other non-operating income, net	(324		)	3,160			(54		)	4,943

(LOSS) INCOME BEFORE INCOME TAXES	(104,256		)	6,750			(140,283		)	72,076
Income tax (benefit) provision	(16,272		)	4,213			(23,552		)	28,512

CONSOLIDATED NET (LOSS) INCOME	$	(87,984	)	$	2,537		$	(116,731	)	$	43,564
CONSOLIDATED NET (LOSS) INCOME PER SHARE
CONSOLIDATED NET (LOSS) INCOME PER SHARE, BASIC	$	(0.70	)	$	0.02		$	(0.93	)	$	0.35
CONSOLIDATED NET (LOSS) INCOME PER SHARE, DILUTED	$	(0.70	)	$	0.02		$	(0.93	)	$	0.35

SHARES USED IN COMPUTING NET (LOSS) INCOME PER SHARE
BASIC	125,332			124,660			125,286			124,541
DILUTED	125,332			125,194			125,286			124,855

COMPREHENSIVE (LOSS) INCOME
Consolidated net (loss) income	$	(87,984	)	$	2,537		$	(116,731	)	$	43,564
Unrealized holding (loss) gain on available-for-sale securities, net of tax of $1 and ($85) for the three months ended June 30, 2018 and 2017, and $1 and ($160) for the six month periods ended June 30, 2018 and 2017 respectively.	(4		)	144			(5		)	272
Foreign currency translation (loss) gain	(6,350		)	1,239			(7,198		)	5,265
Pension liability adjustment gain, net of tax of ($1) and ($6) for the three months ended June 30, 2018 and 2017, and ($2) and ($63) for the six month periods ended June 30, 2018 and 2017 respectively.	4			24			8			247
COMPREHENSIVE (LOSS) INCOME	$	(94,334	)	$	3,944		$	(123,926	)	$	49,348

See notes to condensed consolidated financial statements.

[5]

AKORN, INC.

CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS’ EQUITY

FOR THE SIX MONTHS ENDED JUNE 30, 2018

(In Thousands)



	Shares		Common Stock			Retained Earnings			Other Comprehensive Loss			Total
BALANCES AT DECEMBER 31, 2017	125,091		$	550,472		$	294,741		$	(13,968	)	$	831,245
Consolidated net (loss)	—		—			(116,731		)	—			(116,731		)
Exercise of stock options	22		546			—			—			546
Compensation and share issuances related to restricted stock awards	170		5,817			—			—			5,817
Stock-based compensation expense - stock options	—		5,636			—			—			5,636
Foreign currency translation loss	—		—			—			(7,198		)	(7,198		)
Stock compensation plan withholdings for employee taxes	(25	)	(292		)	—			—			(292		)
Unrealized holding loss on available-for-sale securities	—		—			—			(5		)	(5		)
Akorn AG pension liability adjustment	—		—			—			8			8
Employee stock purchase plan	146		2,809			—			—			2,809
BALANCES AT JUNE 30, 2018 (unaudited)	125,404		$	564,988		$	178,010		$	(21,163	)	$	721,835

See notes to condensed consolidated financial statements.

[6]

AKORN, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In Thousands)

(Unaudited)



	Six Months Ended June 30,
	2018			2017
OPERATING ACTIVITIES:
Consolidated net (loss) income	$	(116,731	)	$	43,564
Adjustments to reconcile consolidated net income to net cash (used in) provided by operating activities:
Depreciation and amortization	40,439			42,212
Amortization of debt financing costs	2,608			2,608
Impairment of intangible assets	83,349			8,079
Non-cash stock compensation expense	11,453			9,844
Income from available-for-sale securities	—			(3,032		)
Deferred income taxes, net	(24,512		)	(2,341		)
Loss on sale of available-for-sale securities	—			196
Other	481			(288		)
Changes in operating assets and liabilities:
Trade accounts receivable	(45,893		)	105,848
Inventories, net	(7,735		)	(6,225		)
Prepaid expenses and other current assets	8,176			2,078
Trade accounts payable	602			(13,465		)
Accrued expenses and other liabilities	16,490			(30,051		)
NET CASH (USED IN) PROVIDED BY OPERATING ACTIVITIES	$	(31,273	)	$	159,027
INVESTING ACTIVITIES:
Proceeds from disposal of assets	20			4,811
Payments for intangible assets	(50		)	(200		)
Purchases of property, plant and equipment	(35,862		)	(50,072		)
NET CASH USED IN INVESTING ACTIVITIES	$	(35,892	)	$	(45,461	)
FINANCING ACTIVITIES:
Proceeds from the exercise of stock options	254			6,897
Payment of contingent acquisition liabilities	(4,793		)	—
Lease payments	(6		)	—
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES	$	(4,545	)	$	6,897
Effect of exchange rate changes on cash and cash equivalents	(560		)	626
(DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	$	(72,270	)	$	121,089
Cash and cash equivalents, and restricted at beginning of period	369,889			204,034
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH AT END OF PERIOD	$	297,619		$	325,123
SUPPLEMENTAL DISCLOSURES:
Amount paid for interest	$	25,462		$	22,124
Amount paid for income taxes, net	$	9,260		$	43,901
Additional capital expenditures included in accounts payable	$	12,010		$	8,806

See notes to condensed consolidated financial statements.

[7]

AKORN, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 1 — Business and Basis of Presentation

Business: Akorn, Inc., together with its wholly-owned subsidiaries (collectively “Akorn,” the “Company,” “we,” “our” or “us”) is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, branded as well as private-label over-the-counter consumer health products and animal health pharmaceuticals. We are an industry leader in the development, manufacturing and marketing of specialized generic pharmaceutical products in alternative dosage forms. We focus on difficult-to-manufacture sterile and non-sterile dosage forms including, but not limited to, ophthalmics, injectables, oral liquids, otics, topicals, inhalants and nasal sprays.

Akorn is a Louisiana corporation founded in 1971 in Abita Springs, Louisiana. In 1997, we relocated our corporate headquarters to the Chicago, Illinois area and currently maintain our principal corporate offices in Lake Forest, Illinois. We operate pharmaceutical manufacturing facilities in Decatur, Illinois; Somerset, New Jersey; Amityville, New York; Hettlingen, Switzerland; and Paonta Sahib, Himachal Pradesh, India. We operate a central distribution warehouse in Gurnee, Illinois and additional distribution facilities in Amityville, New York and Decatur, Illinois. Our research and development (“R&D”) centers are located in Vernon Hills, Illinois and Cranbury, New Jersey. We maintain other corporate offices in Ann Arbor, Michigan and Gurgaon, Haryana, India.

During the three and six month periods ended June 30, 2018 and 2017, the Company reported results for two reportable segments: Prescription Pharmaceuticals and Consumer Health. For further detail concerning our reportable segments please see Part I, Item 1, Note 10 - “Segment Information.”

Our common shares are traded on The NASDAQ Global Select Market under the ticker symbol AKRX. Our principal corporate office is located at 1925 West Field Court Suite 300, Lake Forest, Illinois 60045 with telephone number (847) 279-6100.

Merger Agreement: On April 24, 2017, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Fresenius Kabi AG, a German stock corporation (“Parent”), Quercus Acquisition, Inc., a Louisiana corporation and wholly-owned subsidiary of Parent (“Merger Sub”) and, solely for purposes of Article VIII thereof, Fresenius SE & Co. KGaA, a German partnership limited by shares. The Merger Agreement, which has been adopted by the Board of Directors of the Company, provides for the merger of Merger Sub with and into the Company (the “Merger”), with the Company surviving the Merger as a wholly-owned subsidiary of Parent. On July 19, 2017, the Company's shareholders voted to approve the Merger Agreement.

Subject to the terms and conditions set forth in the Merger Agreement, at the effective time of the Merger (the “Effective Time”), each of the Company’s issued and outstanding shares of common stock, no par value per share (the “Shares”) (other than Shares owned by the Company or by Parent, Merger Sub or any direct or indirect wholly-owned subsidiary of the Company or of Parent (other than Merger Sub) immediately prior to the Effective Time), will be converted into the right to receive $34.00 in cash per Share (the “Merger Consideration”), without interest.

Completion of the Merger is subject to customary closing conditions, including (1) there being no judgment or law enjoining or otherwise prohibiting the consummation of the Merger and (2) the expiration of the waiting period applicable to the Merger under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. The obligation of each of the Company and Parent to consummate the Merger is also conditioned on the other party’s representations and warranties being true and correct (subject to certain materiality exceptions) and the other party having performed in all material respects its obligations under the Merger Agreement.

The Merger Agreement contains representations and warranties and covenants of the parties customary for a transaction of this nature. Among other things, Parent has agreed to promptly take all actions necessary to obtain antitrust approval of the Merger, including (i) entering into consent decrees or undertakings with a regulatory authority, (ii) divesting or holding separate any assets or businesses of Parent or the Company, (iii) terminating existing contractual relationships or entering into new contractual relationships, (iv) effecting any other change or restructuring of Parent or the Company and (v) defending through litigation any claim asserted by a regulatory authority that would prevent the closing of the Merger.

[8]

Fresenius SE & Co. KGaA, in the Court of Chancery of the State of Delaware for breach of contract and declaratory judgment. The complaint alleges, among other things, that (i) the defendants anticipatorily breached their obligations under the Merger Agreement by repudiating their obligation to close the Merger, (ii) the defendants knowingly and intentionally breached their obligations under the Merger Agreement by working to slow the antitrust approval process and by engaging in a series of actions designed to hamper and ultimately block the Merger and (iii) Akorn has performed its obligations under the Merger Agreement, and is ready, willing and able to close the Merger. The complaint seeks, among other things, a declaration that Fresenius Kabi AG's termination is invalid, an order enjoining the defendants from terminating the Merger Agreement, and an order compelling the defendants to specifically perform their obligations under the Merger Agreement to use reasonable best efforts to consummate and make effective the Merger. On April 30, 2018, the defendants filed a verified counterclaim alleging that, due primarily to purported data integrity deficiencies at Akorn, the Company had breached representations and warranties and covenants in the Merger Agreement, and that it had experienced a material adverse effect. The verified counterclaim seeks, among other things, a declaration that defendants’ purported termination of the Merger Agreement was valid and that defendants are not obligated to consummate the transaction.

Following expedited discovery, from July 9 to 13, 2018, the Court of Chancery held a trial on the parties’ claims (collectively, the “Delaware Action”). At the conclusion of trial, the Court of Chancery ordered post-trial briefing, which is scheduled to be completed on August 20, 2018. The Court has scheduled a post-trial hearing for August 23, 2018. Akorn expects to receive the Court’s ruling after the post-trial hearing. Any decision by the Court of Chancery will be subject to a potential appeal to the Delaware Supreme Court.

Basis of Presentation: The Company’s financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") for interim financial information and accordingly do not include all the information and footnotes required by GAAP for annual financial statements. In the opinion of management, all adjustments of a normal and recurring nature considered necessary for a fair presentation have been included in these financial statements. Operating results for the three and six month periods ended June 30, 2018 are not necessarily indicative of the results that may be expected for the full year. For further information, refer to the consolidated financial statements and footnotes for the year ended December 31, 2017, included in the Company’s Annual Report on Form 10-K filed on February 28, 2018.

Note 2 — Summary of Significant Accounting Policies

Consolidation: The accompanying condensed consolidated financial statements include the accounts of Akorn, Inc. and its wholly-owned domestic and foreign subsidiaries. All inter-company transactions and balances have been eliminated in consolidation, and the financial statements of Akorn India Private Limited ("AIPL") and Akorn AG have been translated from Indian Rupees to U.S. dollars and Swiss Francs to U.S. dollars, respectively, based on the currency translation rates in effect during the period or as of the date of consolidation, as applicable. The Company has no involvement with variable interest entities.

Use of Estimates: The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.

Significant estimates and assumptions for the Company relate to the allowances for chargebacks, rebates, product returns, coupons, promotions and doubtful accounts, as well as the reserve for slow-moving and obsolete inventories, the carrying value and lives of intangible assets, the useful lives of fixed assets, the carrying value of deferred income tax assets and liabilities, the assumptions underlying share-based compensation, accrued but unreported employee benefit costs and assumptions underlying the accounting for business combinations.

Going Concern: In connection with the preparation of the financial statements as of and for the six month period ended June 30, 2018, the Company conducted an evaluation as to whether there were conditions and events, considered in the aggregate, which raised substantial doubt as to the entity's ability to continue as a going concern within one year after the date of the issuance, or the date of availability, of the financial statements to be issued, noting that there did not appear to be evidence of substantial doubt of the entity's ability to continue as a going concern.

Revenue Recognition: Revenue is recognized at a point in time upon the transfer of control of the Company’s products, which occurs upon delivery for substantially all of the Company’s sales. The promises within the contract that are distinct are primarily the Company’s supply of products, which represents a single performance obligation. The consideration the Company receives in exchange for its goods or services is only recognized when it is probable that a significant reversal will not occur.

[9]

The consideration to which the Company expects to be entitled includes a stated list price, less various forms of variable consideration. The Company makes significant estimates for related variable consideration at the point of sale, including chargebacks, rebates, product returns, other discounts and allowances. All sales taxes are excluded from the transaction price. The Company expenses contract fulfillment costs when incurred since the amortization period would have been less than one year. Payment terms are primarily less than 90 days. See Note 16 – Recently Issued and Adopted Accounting Pronouncements for the discussion of the adoption of Accounting Standard Codification ("ASC") Topic 606 Revenue from Contracts with Customers.

Provision for estimated chargebacks, rebates, discounts, managed care rebates, product returns and doubtful accounts is made at the time of sale and is analyzed and adjusted, if necessary, at each balance sheet date.

Freight: The Company records shipping and handling expense related to product sales as cost of sales.

Cash and Cash Equivalents: The Company considers all unrestricted, highly liquid investments with maturity of three months or less when acquired, to be cash and cash equivalents. At June 30, 2018 and December 31, 2017, approximately $0.8 million and $1.8 million, respectively, of cash held by AIPL was restricted, and was reported within prepaid expenses and other current assets.

The following table sets forth the components of the Company’s cash, cash equivalents, and restricted cash as reported in the consolidated statement of cash flows for the six month periods ended June 30, 2018 and 2017 (in thousands):



Cash, Cash Equivalents, and Restricted Cash	Six Months Ended June 30,
	2018		2017
Cash and cash equivalents	$	296,782	$	322,742
Restricted cash	837		2,381
Total cash, cash equivalents, and restricted cash	$	297,619	$	325,123

Accounts Receivable: Trade accounts receivable are stated at their net realizable value. The nature of the Company’s business involves, in the ordinary course, significant judgments and estimates relating to chargebacks, coupon redemption, product returns, rebates, discounts given to customers and allowances for doubtful accounts. Certain rebates, chargebacks and other credits are recorded as deductions to the Company’s trade accounts receivable where applicable, based on product and customer specific terms.

Unless otherwise noted, the provisions and allowances for the following customer deductions are reflected in the accompanying consolidated financial statements as reductions of revenues and trade accounts receivable, respectively.

Chargebacks: The Company enters into contractual agreements with certain third parties such as retailers, hospitals, group-purchasing organizations (“GPOs”) and managed care organizations to sell certain products at predetermined prices. Similarly, we maintain an allowance for rebates and discounts related to billbacks, wholesaler fee for service contracts, GPO administrative fees, government programs, prompt payment and other adjustments with certain customers. Most of the parties have elected to have these contracts administered through wholesalers that buy the product from the Company and subsequently sell it to these third parties. As noted elsewhere, these wholesalers represent a significant percentage of the Company’s gross sales. When a wholesaler sells products to one of these third parties that are subject to a contractual price agreement, the difference between the price paid to the Company by the wholesaler and the price under the specific contract is charged back to the Company by the wholesaler. This process typically takes four to six weeks, but for some products may extend to twelve weeks. The Company tracks sales and submitted chargebacks by product number and contract for each wholesaler. Utilizing this information, the Company estimates a chargeback percentage for each product and records an allowance as a reduction to gross sales when the Company records its sale of the products. The Company reduces the chargeback allowance when a chargeback request from a wholesaler is processed. Actual chargebacks processed by the Company can vary materially from period to period based upon actual sales volume through the wholesalers. However, the Company’s provision for chargebacks is fully reserved for at the time revenues are recognized.

Management obtains product inventory reports from certain wholesalers to aid in analyzing the reasonableness of the chargeback allowance and to monitor whether wholesaler inventory levels do not significantly exceed customer demand. The Company assesses the reasonableness of its chargeback allowance by applying a product chargeback percentage that is based on a combination of historical activity and future price and mix expectations to the quantities of

[10]

inventory on hand at the wholesalers according to wholesaler inventory reports. In addition, the Company estimates the percent of gross sales generated through direct and indirect sales channels and the percent of contract vs. non-contract revenue in the period, as these each affect the estimated reserve calculation. In accordance with its accounting policy, the Company also estimates the percent of wholesaler inventory that will ultimately be sold to third parties that are subject to contractual price agreements based on a trend of such sales through wholesalers. The Company uses this percentage estimate until historical trends indicate that a revision should be made. On an ongoing basis, the Company evaluates its actual chargeback rate experience, and new trends are factored into its estimates each quarter as market conditions change.

For the three month period ended June 30, 2018, the Company incurred a chargeback provision of $222.5 million, or 43.8% of gross sales of $507.8 million, compared to $237.3 million, or 41.8% of gross sales of $567.1 million in the prior year period. We note that the dollar decrease and percent increase in the comparative period was the result of gross sales decreases and product mix shifts to products with higher chargeback expense percentages. The Company ensures that this rate as a percent of gross sales is reasonable through inspection of contractual obligations, review of historical trends and evaluation of recent activity. Furthermore, other events that could materially alter chargeback rates include: changes in product pricing as a result of competitive market dynamics or negotiations with customers, changes in demand for specific products due to external factors such as competitor supply position or consumer preferences, customer shifts in buying patterns from direct to indirect through wholesalers, which could either individually or in aggregate increase or decrease the chargeback rate depending on the direction and velocity of the change(s).

To better understand the impact of changes in chargeback reserve based on circumstances that are not fully outside the Company’s control, for instance, the ratio of sales subject to chargeback to indirect sales, the Company performs a sensitivity analysis. Holding all other assumptions constant, for a 480 basis point (“BP”) change in the ratio of sales subject to chargeback to indirect sales would increase the chargeback reserve by $0.5 million or decrease the chargeback reserve by $2.6 million depending on the change in the direction of the ratio. Fundamentally, the BP change calculation is determined based on the six month trend of the average ratio of sales subject to chargeback to indirect sales. Due to the competitive generic pharmaceutical industry and our recent experience with wholesalers’ strategy and shifts in contracted and non-contracted indirect sales, we believe that the six month trend of the proportion of direct to indirect sales provides a representative basis for sensitivity analysis.

Rebates, Administrative Fees and Others: The Company maintains an allowance for rebates, administrative fees and others, related to contracts and other rebate programs that it has in place with certain customers. Rebates, administrative fees and other percentages vary by product and by volume purchased by each eligible customer. The Company tracks sales by product number for each eligible customer and then applies the applicable rebate, administrative fees and other percentage, using both historical trends and actual experience to estimate its rebates, administrative fees and others allowances. The Company reduces gross sales and increases the rebates, administrative fees and others allowance by the estimated rebates, administrative fees and others amounts when the Company sells its products to eligible customers. The Company reduces the rebate allowance when it processes a customer request for a rebate. At each balance sheet date, the Company analyzes the allowance for rebates, administrative fees and others against actual rebates processed and makes adjustments as appropriate. The amount of actual rebates processed can vary materially from period to period as discussed below.

The allowances for rebates, administrative fees and others further takes into consideration price adjustments which are credits issued to reflect increases or decreases in the invoice or contract prices of the Company’s products. In the case of a price decrease, a shelf-stock adjustment credit may be given for product remaining in customer’s inventories at the time of the price reduction and is reserved at the point of sale. Contractual price protection results in a similar credit when the invoice or contract prices of the Company’s products increase, effectively allowing customers to purchase products at previous prices for a specified period of time. Amounts recorded for estimated shelf-stock adjustments and price protections are based upon specified terms with direct customers, estimated changes in market prices, and estimates of inventory held by customers. The Company regularly monitors these and other factors and evaluates the reserve as additional information becomes available.

Similar to rebates, the reserve for administrative fees and others represents those amounts processed related to contracts and other fee programs which have been in place with certain entities, but they are settled through cash payment to these entities and accordingly are accounted for as a current liability. Otherwise, administrative fees and others operate similarly to rebates.

For the three month period ended June 30, 2018, the Company incurred rebates, administrative and others fees of $75.1 million, or 14.8% of gross sales of $507.8 million, compared to $109.8 million, or 19.4% of gross sales of $567.1

[11]

million in the prior year period. We note that the dollar and percent decreases from the comparative period were the result of gross sales decreases and product mix shifts to products with lower rebates, administrative fees and others expense percentages. Additionally, a change in contractual terms with a major customer in the first quarter of 2018 resulted in a decrease in rebates, which is also a contributing factor in the variances between the two periods compared. The Company ensures that this rate as a percent of gross sales is reasonable through inspection of contractual obligations, review of historical trends and evaluation of recent activity. Furthermore, other events that could materially alter rebates, administrative fees and others rates include: changes in product pricing as a result of competitive market dynamics or negotiations with customers, changes in demand for specific products due to external factors such as competitor supply position or consumer preferences, customer shifts in buying patterns from direct to indirect through wholesalers, which could either individually or in aggregate increase or decrease the rebate rate depending on the direction and velocity of the change(s).

To better understand the impact of changes in reserves for rebates, administrative fees and others based on circumstances that are not fully outside the Company’s control, for instance, the proportion of direct to indirect sales subject to rebates, administrative fees and others, the Company performs a sensitivity analysis. Holding all other assumptions constant, for a 480 BP change in the ratio of sales subject to rebates, administrative fees and others to indirect sales would increase the reserve for rebates, administrative fees and others by $0.1 million or decrease the same reserve by $0.5 million depending on the direction of the change in the ratio. Fundamentally, the BP change calculation is determined based on the six month trend of the average ratio of sales subject to rebates, administrative fees and others to indirect sales. Due to the competitive generic pharmaceutical industry and our recent experience with wholesalers’ strategy and shifts in contracted and non-contracted indirect sales, we believe the six month trend of the average ratio of sales subject to rebates, administrative fees and others to indirect sales provides a representative basis for sensitivity analysis.

Sales Returns: Certain of the Company’s products are sold with the customer having the right to return the product within specified periods. Provisions are made at the time of sale based upon historical experience. Historical factors such as one-time recall events as well as pending new developments like comparable product approvals or significant pricing movement that may impact the expected level of returns are taken into account to determine the appropriate reserve estimate at each balance sheet date. As part of the evaluation of the reserve required, the Company considers actual returns to date that are in process, the expected impact of any product recalls and the amount of wholesaler’s inventory to assess the magnitude of unconsumed product that may result in sales returns to the Company in the future. The sales returns level can be impacted by factors such as overall market demand and market competition and availability for substitute products which can increase or decrease the pull through for sales of the Company’s products and ultimately impact the level of sales returns.

For the three month period ended June 30, 2018, the Company incurred a return provision of $6.1 million, or 1.2% of gross sales of $507.8 million, compared to $8.1 million, or 1.4% of gross sales of $567.1 million in the prior year period. We note that the dollar and percent decreases in the comparative period was the result of gross sales decreases and product mix shifts to products with lower return rates. The Company ensures that this rate as a percent of gross sales is reasonable through inspection of historical trends and evaluation of recent activity. Furthermore, other events that could materially alter return rates include: acquisitions and integration activities that consolidate dissimilar contract terms and could decrease the return rate as typically the Company purchases smaller entities with less contracting power; and consumer demand shifts by products, which could either increase or decrease the return rate depending on the product or products specifically demanded and ultimately returned.

To better understand the impact of changes in return reserve based on certain circumstances, the Company performs a sensitivity analysis. Holding all other assumptions constant, for an average one month change in the lag from the time of sale to the time the product return is processed, this change would result in an increase of $1.5 million or decrease of $1.6 million in return reserve expense if the lag increases or decreases, respectively. The average one month change in the lag from the time of sale to the time the product return is processed was determined based on the average variances of the last six-month historical activities. Due to the change in the volume and type of products sold by the Company in the recent past, we have determined that the lag calculation provides a reasonable basis for sensitivity analysis.

Allowance for Coupons, Advertising, Promotions and Co-Pay Discount Cards: The Company issues coupons from time to time that are redeemable against certain of our Consumer Health products. In addition to couponing, from time to time the Company authorizes various retailers to run in-store promotional sales and co-pay discount of its products. At the point of sale, the Company records an estimate of the dollar value of coupons expected to be redeemed, the dollar amount owed back to the retailer and co-pay discount as variable consideration since the Company intends to continuously issue coupons, advertising promotion and co-pay discount from time to time. This coupon estimate is based on historical experience and is adjusted as needed based on actual redemptions. Upon receiving confirmation that an advertising promotion was run, the Company adjusts

[12]

the estimate of the dollar amount expected to be owed back to the retailer as needed. This estimate is then adjusted to actual upon receipt of an invoice from the retailer. Additionally, the Company provides consumer co-pay discount cards, administered through outside agents to provide discounted products when redeemed. The Company records an estimate of the dollar value of co-pay discounts expected to be utilized based on historical experience and is adjusted as needed based on actual experience.

Doubtful Accounts: Provisions for doubtful accounts, which reflect trade receivable balances owed to the Company that are believed to be uncollectible, are recorded as a component of selling, general and administrative ("SG&A") expenses. In estimating the allowance for doubtful accounts, the Company considers its historical experience with collections and write-offs, the credit quality of its customers and any recent or anticipated changes thereto, and the outstanding balances and past due amounts from its customers. Note that in the ordinary course of business, and consistent with our peers, we may from time to time offer extended payment terms to our customers as an incentive for new product launches or in other circumstances in accordance with standard industry practices. These extended payment terms do not represent a significant risk to the collectability of accounts receivable as of the period-end. Accounts are considered past due when they remain uncollected beyond the due date specified in the applicable contract or on the applicable invoice, whichever is deemed to take precedence.

Inventories: Inventories are stated at the lower of cost and net realizable value ("NRV") (see Note 5 - Inventories, net). The Company maintains an allowance for slow-moving and obsolete inventory as well as inventory where the cost is in excess of its NRV. For finished goods inventory, the Company estimates the amount of inventory that may not be sold prior to its expiration or is slow-moving based upon recent sales activity by unit and wholesaler inventory information. The Company also analyzes its raw material and component inventory for slow-moving items and NRV.

The Company capitalizes inventory costs associated with its products prior to regulatory approval when, based on management judgment, future commercialization is considered probable and future economic benefit is expected to be realized. The Company assesses the regulatory approval process and where the product stands in relation to that approval process including any known constraints or impediments to approval. The Company also considers the shelf life of the product in relation to the product timeline for approval.

Property, Plant and Equipment: Property, plant and equipment is stated at cost, less accumulated depreciation. Depreciation is provided using the straight-line method in amounts considered sufficient to amortize the cost of the assets to operations over their estimated useful lives.

Intangible Assets: Intangible assets consist primarily of goodwill, which is carried at its initial value, In-Process Research and Development ("IPR&D"), which is accounted for as an indefinite-lived intangible asset, subject to impairment testing until completion or abandonment of the project, and product licensing costs, trademarks and other such costs, which are capitalized and amortized on a straight-line basis over their useful lives, normally ranging from one year to thirty years. The Company regularly assesses its amortizable intangible assets for impairment based on several factors, including estimated fair value and anticipated cash flows. If the Company incurs additional costs to renew or extend the life of an intangible asset, such costs are added to the remaining unamortized cost of the asset, if any, and the sum is amortized over the extended remaining life of the asset. Goodwill is tested for impairment annually or more frequently if changes in circumstances or the occurrence of events suggest that impairment may exist. The Company uses widely accepted valuation techniques to determine the fair value of its reporting units used in its annual goodwill impairment analysis. The Company’s valuation is primarily based on qualitative and quantitative assessments regarding the fair value of the reporting unit relative to its carrying value. The Company models the fair value of the reporting unit based on projected earnings and cash flows of the reporting unit.

Impairments of IPR&D are recorded within R&D expenses in the Consolidated Statements of Comprehensive Income, while all other impairments of intangible assets are recorded within the impairment of intangible assets line.

Net (loss) Income Per Common Share: Basic net income (loss) per common share is based upon the weighted average common shares outstanding. Diluted net income (loss) per common share is based upon the weighted average number of common shares outstanding, including the dilutive effect, if any, of stock options and restricted stock using the treasury stock method. Anti-dilutive shares are excluded from the computation of diluted net income (loss) per share.

Income Taxes: Income taxes are accounted for under the asset and liability method. Deferred income tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities, and net operating loss and other tax credit carry-forwards. These items are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company records a valuation allowance to reduce the deferred income tax assets to the amount that is more likely than not to be realized. On December 22, 2017, the Tax Cuts and Jobs Act (the “Tax Act”) was enacted into law and the new legislation contains several key tax provisions including a one-time mandatory transition tax on accumulated foreign earnings and a reduction of the corporate income tax rate to 21%, among others. We are

[13]

required to recognize the effect of the tax law changes in the period of enactment, such as re-measuring our U.S. deferred tax assets and liabilities and reassessing the net realizability of our deferred tax assets and liabilities. The Company’s foreign subsidiaries do not have accumulated earnings that can be distributed; therefore, the provisions of the Act related to the repatriation of foreign earnings are not applicable to the Company at December 31, 2017 or June 30, 2018. In December 2017, the SEC staff issued Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (SAB 118), which allows us to record provisional amounts during a measurement period not to extend beyond one year of the enactment date. See Note 14 — Income Taxes for more information.

Fair Value of Financial Instruments: The Company applies ASC 820 - Fair Value Measurement, which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC 820 - Fair Value Measurement defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Company’s principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 - Fair Value Measurement generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity’s own assumptions based on market data and the entity’s judgments about the assumptions that market participants would use in pricing the asset or liability, and are to be developed based on the best information available in the circumstances.

The valuation hierarchy is composed of three levels. The classification within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The levels within the valuation hierarchy are described below:


-	Level 1—Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities. The carrying value of the Company's cash and cash equivalents are considered Level 1 assets.


-	Level 2—Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as directly or indirectly observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals. The Company has no Level 2 assets or liabilities in any of the periods presented.

Level 3—Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities. The portion of the fair valuation of the available-for-sale investment held in shares of Nicox stock that is subject to a lock-up provision is considered a Level 3 asset. The additional consideration payable as a result of prior years' acquisitions and other insignificant contingent amounts are considered Level 3 liabilities.

The following table summarizes the basis used to measure the fair values of the Company’s financial instruments (amounts in thousands):



			Fair Value Measurements at Reporting Date, Using:
Description	June 30, 2018		Quoted Prices in Active Markets for Identical Items (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Cash and cash equivalents	$	296,782	$	296,782	$	—	$	—
Nicox stock with lockup provisions	29		—		—		29
Total assets	$	296,811	$	296,782	$	—	$	29

Purchase consideration payable	$	201	$	—	$	—	$	201
Total liabilities	$	201	$	—	$	—	$	201

[14]



Description	December 31, 2017		Quoted Prices in Active Markets for Identical Items (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Cash and cash equivalents	$	368,119	$	368,119	$	—	$	—
Nicox stock with lockup provisions	35		—		—		35
Total assets	$	368,154	$	368,119	$	—	$	35

Purchase consideration payable	$	3,901	$	—	$	—	$	3,901
Total liabilities	$	3,901	$	—	$	—	$	3,901

As of June 30, 2018, the purchase consideration payable balance is attributed to a supply obligation related to one of our divested products.

Stock-Based Compensation: Stock-based compensation cost is estimated at grant date based on the fair value of the award, and the cost is recognized as expense ratably over the vesting period. The Company uses the Black-Scholes model for estimating the grant date fair value of stock options. Determining the assumptions to be used in the model is highly subjective and requires judgment. The Company uses an expected volatility that is based on the historical volatility of its common stock. The expected life assumption is based on historical employee exercise patterns and employee post-vesting termination behavior. The risk-free interest rate for the expected term of the option is based on the average market rate on U.S. Treasury securities of similar term in effect during the quarter in which the options were granted. The dividend yield reflects the Company’s historical experience as well as future expectations over the expected term of the option. The Company estimates forfeitures at the time of grant and revises the estimate in subsequent periods, as necessary, if actual forfeitures differ from initial estimates.

Note 3 — Stock Options, Restricted Stock Units and Employee Stock Purchase Plan

The Company maintains equity compensation plans that allow the Company’s Board of Directors to grant stock options and other equity awards to eligible employees, officers, directors and consultants. On April 27, 2017, the Company’s shareholders voted to approve the Akorn, Inc. 2017 Omnibus Incentive Compensation Plan (the “Omnibus Plan”). Under the Omnibus Plan, 8.0 million shares of the Company’s common stock were made available for issuance pursuant to equity awards. The Omnibus Plan replaced the Akorn, Inc. 2014 Stock Option Plan (the "2014 Plan"), which was approved by shareholders at the Company's 2014 Annual Meeting of Shareholders on May 2, 2014 and subsequently amended by proxy vote of the Company’s shareholders on December 16, 2016. The 2014 Plan had reserved 7.5 million shares for issuance upon the grant of stock options, restricted stock units (“RSUs”), or various other instruments to directors, employees and consultants. Following shareholder approval of the Omnibus Plan, no new awards could be granted under the 2014 Plan, although previously granted awards remain outstanding pursuant to their original terms. As of June 30, 2018, there were approximately 3.7 million stock options and 0.2 million RSU shares outstanding under the 2014 Plan. The 2014 Plan had replaced the Amended and Restated Akorn, Inc. 2003 Stock Option Plan (the “2003 Plan”), which expired on November 6, 2013. As of June 30, 2018, approximately sixteen thousand stock options were outstanding under the 2003 Plan.

Under the Omnibus Plan, 2.0 million RSUs have been granted to employees and directors, of which approximately 0.2 million have vested and been released, and 0.1 million have been forfeited, leaving 1.7 million RSUs outstanding as of June 30, 2018. No stock options have been granted under the Omnibus Plan. As of June 30, 2018, approximately 6.1 million shares remain available for future award grants under the Omnibus Plan.

The Company accounts for stock-based compensation in accordance with ASC Topic 718 - Compensation — Stock Compensation. Accordingly, stock-based compensation cost is estimated at the grant date based on the fair value of the award, and the cost is recognized as expense ratably over the vesting period. The Company uses the Black-Scholes model for estimating the grant date fair value of stock options. Determining the assumptions that enter into the model is highly subjective and requires judgment. The Company uses an expected volatility that is based on the historical volatility of its stock. The expected life assumption is based on historical employee exercise patterns and employee post-vesting termination behavior. The risk-free interest rate for the expected term of the option is based on the average market rate on U.S. Treasury securities in effect during the quarter in which the options were granted. The dividend yield reflects historical experience as well as future

[15]

expectations over the expected term of the option. The Company estimates forfeitures at the time of grant and revises in subsequent periods, as necessary, if actual forfeitures differ from those estimates.

The Company uses the single-award method for allocating compensation cost related to stock options to each period. The following table sets forth the components of the Company’s share-based compensation expense for the three and six month periods ended June 30, 2018 and 2017 (in thousands):



	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017
Stock options	$	2,477	$	2,956	$	5,636	$	6,270
Employee stock purchase plan	—		275		—		537
Restricted stock units	3,468		1,904		5,817		3,037
Total stock-based compensation expense	$	5,945	$	5,135	$	11,453	$	9,844

Stock Option awards

From time to time, the Company has granted stock option awards to certain employees, executives and directors. No stock options were granted in 2018. Set forth in the following table are the weighted-average assumptions used in estimating the grant date fair value of the stock options granted under the Company's equity compensation plans during the six month period ended June 30, 2017, along with the weighted-average grant date fair values:



	Three Months Ended June 30,						Six Months Ended June 30,
	2018			2017			2018			2017
Expected volatility	—		%	—		%	—		%	50		%
Expected life (in years)	—			—			—			4.8
Risk-free interest rate	—		%	—		%	—		%	1.75		%
Dividend yield	—			—			—			—
Fair value per stock option	$	—		$	—		$	—		$	9.25
Forfeiture rate	—		%	—		%	—		%	8		%

The table below sets forth a summary of stock option activity within the Company’s stock-based compensation plans for the six month period ended June 30, 2018:



	Number of Options (in thousands)		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (in thousands) (1)
Outstanding at December 31, 2017	4,053		$	28.95	4.56	$	21,459
Granted	—		—
Exercised	(22	)	24.99
Forfeited	(298	)	24.76
Outstanding at June 30, 2018	3,733		$	29.30	4.04	$	—
Exercisable at June 30, 2018	2,164		$	30.08	3.44	$	—

(1) The Aggregate Intrinsic Value of stock options outstanding and exercisable is defined as the difference between the market value of the Company’s common stock as of the date indicated and the exercise price of the stock options. Stock options for which the exercise price exceeded the market price have been omitted. Fluctuations in the intrinsic value of both outstanding and exercisable options may result from changes in underlying stock price and the timing and volume of option grants, exercises and forfeitures.

[16]

During the three month period ended June 30, 2018, no stock options were exercised, while during the six month period ended June 30, 2018, approximately twenty-two thousand stock options were exercised resulting in cash payments to the Company of $0.5 million. These stock option exercises generated tax deductible expense of $0.2 million. During the three and six month periods ended June 30, 2017, 0.4 million and 0.5 million stock options were exercised resulting in cash payments to the Company of $5.9 million and $7.1 million, respectively. These stock option exercises generated tax deductible expense of $6.1 million and $6.9 million, respectively.

Restricted Stock Unit awards

From time to time, the Company has granted RSUs to certain employees, executives and directors. The majority of the grants to employees and executives are pursuant to the Company's Long-Term Incentive Plans (the "LTIPs"), which call for annual grants of RSUs to all eligible employees and executives. The RSU awards vest 25% per year on each of the first four anniversaries of the grant date. All RSUs are valued at the closing market price of the Company’s common stock on the day of grant and the total value of the units is recognized as expense ratably over the vesting period of the grant. During the six month period ended June 30, 2018, the Company granted 1.3 million RSUs to certain employees, executives and directors.

Set forth below is a summary of unvested RSU activity during the six month period ended June 30, 2018:



	Number of Units (in thousands)	Weighted Average Per Share Grant Date Fair Value
Unvested at December 31, 2017	888	$	32.56
Granted	1,308	$	19.28
Vested	(170)	$	32.40
Forfeited	(63)	$	25.09
Unvested at June 30, 2018	1,963	$	23.96

Employee Stock Purchase Plan

The 2016 Akorn, Inc. Employee Stock Purchase Plan (the “ESPP”) permits eligible employees to acquire shares of the Company’s common stock through payroll deductions. The ESPP has been structured to qualify under Section 423 of the Internal Revenue Code (“IRC”). Employees who elect to participate in the ESPP may withhold from 1% to 15% of eligible wages toward the purchase of stock. Shares will be purchased at a 15% discount off the lesser of the market price at the beginning or the ending of the applicable offering period. The ESPP is designed with two offering periods each year, one running from January 1st to December 31st and the other running from July 1st to December 31st. In a given year, employees may enroll in only one offering period, not both. Per IRC rules, annual purchases per employee are limited to $25,000 worth of stock, valued as of the beginning of the offering period. Accordingly, with the 15% discount, employees may withhold no more than $21,250 per year toward the purchase of stock under the ESPP. Employees are further limited to purchasing no more than 15,000 shares of stock per year. A total of 2.0 million shares of the Company’s stock have been set aside for issuance under the ESPP, of which 146,247 shares have been issued to date. The ESPP was approved by vote of the Company’s shareholders on December 16, 2016.

Pursuant to terms of the Merger Agreement, the Company has not initiated any new offering periods subsequent to entering into the Merger Agreement. Accordingly, no offering periods are currently active under the ESPP.

Note 4 — Accounts Receivable, Sales and Allowances

The nature of the Company’s business inherently involves, in the ordinary course, significant amounts and substantial volumes of transactions and estimates relating to allowances for product returns, chargebacks, rebates, doubtful accounts and discounts given to customers. This is typical of the pharmaceutical industry and is not necessarily specific to the Company. Depending on the product, the end-user customer, the specific terms of national supply contracts and the particular arrangements with the Company’s wholesaler customers, certain rebates, chargebacks and other credits are deducted from the Company’s accounts receivable. The process of claiming these deductions depends on wholesalers reporting to the Company the amount of deductions that were earned under the terms of the respective agreement with the end-user customer (which in turn depends on the specific end-user customer, each having its own pricing arrangement that entitles it to a particular deduction). This process can lead to partial payments to the Company against outstanding invoices as the wholesalers take the claimed deductions at the time of payment.

[17]

With the exception of the provision for doubtful accounts, which is reflected as part of selling, general and administrative expense, the provisions for the following customer reserves are reflected as a reduction of revenues in the accompanying condensed consolidated statements of comprehensive (loss) income. Additionally, with the exception of administrative fees and others, which is included as a current liability, the ending reserve balances are included in trade accounts receivable, net in the Company’s condensed consolidated balance sheets.

Trade accounts receivable, net consists of the following (in thousands):



	June 30, 2018			December 31, 2017
Gross accounts receivable	$	375,051		$	378,759
Less reserves for:
Chargebacks (1)	(68,289		)	(73,984		)
Rebates (1)	(67,766		)	(111,945		)
Product returns	(40,737		)	(41,687		)
Discounts and allowances	(8,215		)	(7,779		)
Advertising and promotions	(2,118		)	(1,301		)
Doubtful accounts	(608		)	(680		)
Trade accounts receivable, net	$	187,318		$	141,383

(1) The reductions in the Chargebacks and Rebates balances as of June 30, 2018 when compared to the December 31, 2017 balance were primarily due to payment timing, product mix, customer mix and lower wholesaler inventory. Additionally, a change in contractual terms with a major customer in the first quarter of 2018 resulted in an increase in chargebacks and a decrease in rebates, which is also a contributing factor in the variances between the two periods compared.

For the three and six month periods ended June 30, 2018 and 2017, the Company recorded the following adjustments to gross sales (in thousands):



	Three Months Ended June 30,						Six Months Ended June 30,
	2018			2017			2018			2017
Gross sales	$	507,819		$	567,112		$	1,028,352		$	1,247,647
Less adjustments for:
Chargebacks (1)	(222,482		)	(237,275		)	(446,445		)	(517,437		)
Rebates, administrative and other fees (1)	(75,094		)	(109,760		)	(167,374		)	(234,138		)
Product returns	(6,133		)	(8,116		)	(13,254		)	(16,533		)
Discounts and allowances	(9,946		)	(10,830		)	(20,183		)	(23,752		)
Advertising, promotions and others	(3,220		)	(1,991		)	(6,089		)	(3,227		)
Revenues, net	$	190,944		$	199,140		$	375,007		$	452,560

(1) The decreases in chargebacks and rebates, administrative and other fees for the three and six month periods ended June 30, 2018 as compared to the same periods in 2017, were primarily due to volume declines as well as product mix and customer mix.

Note 5 — Inventories, Net

The components of inventories are as follows (in thousands):



	June 30, 2018		December 31, 2017
Finished goods	$	84,594	$	79,226
Work in process	15,053		15,447
Raw materials and supplies	91,394		88,895
Inventories, net	$	191,041	$	183,568

[18]

The Company maintains an allowance for excess and obsolete inventory, as well as inventory for which its cost is in excess of its net realizable value. Inventory at June 30, 2018 and December 31, 2017 was reported net of these reserves of $33.5 million and $34.4 million, respectively.

Note 6 — Property, Plant and Equipment, Net

Property, plant and equipment, net consist of the following (in thousands):



	June 30, 2018			December 31, 2017
Land and land improvements	$	17,578		$	17,846
Buildings and leasehold improvements	113,632			106,316
Furniture and equipment	225,203			202,897
Sub-total	356,413			327,059
Accumulated depreciation	(143,750		)	(130,814		)
Property, plant and equipment in service, net	$	212,663		$	196,245
Construction in progress	116,246			117,173
Property, plant and equipment, net	$	328,909		$	313,418

At June 30, 2018 and December 31, 2017, property, plant and equipment, net, with a net carrying value of $86.0 million and $82.8 million, respectively, was located outside the United States.

During the six month period ended June 30, 2018, the increase in Property, Plant and Equipment is due primarily to spending on equipment for compliance with the Drug Supply Chain Security Act ("DSCSA") requirements and expansion initiatives at our Decatur and Somerset manufacturing plants.

At June 30, 2018, the Company had $116.2 million of assets under construction which consisted primarily of investment in building expansions, equipment, and compliance with DSCSA. Depreciation will begin on these assets once they are placed into service. These projects are expected to be completed in 2018 and 2019. The Company assesses its long-lived assets, consisting primarily of property and equipment, for impairment when material events and changes in circumstances indicate that the carrying value may not be recoverable. There were no impairment losses recorded in 2018 or 2017.

The Company recorded depreciation expense of $7.0 million and $5.8 million during the three month periods ended June 30, 2018 and 2017, respectively, and $14.1 million and $11.2 million during the six month periods ended June 30, 2018 and 2017, respectively.

Note 7 — Goodwill and Other Intangible Assets, Net

Intangible assets consist primarily of Goodwill, which is carried at its initial value, subject to evaluation for impairment, In-Process Research and Development (“IPR&D”), which is accounted for as an indefinite-lived intangible asset, subject to impairment testing until completion or abandonment of the project, and product licensing costs, trademarks and other such costs, which are capitalized and amortized on a straight-line basis over their useful lives, ranging from one to thirty years.

During the six month periods ended June 30, 2018 and 2017, accumulated amortization of intangible assets was $244.9 million and $220.6 million, respectively. The Company recorded amortization expense of $13.2 million and $15.5 million during the three month periods ended June 30, 2018 and 2017, respectively, and $26.4 million and $31.0 million during the six month periods ended June 30, 2018 and 2017, respectively.

The Company regularly assesses its amortizable intangible assets for impairment based on several factors, including estimated fair value and anticipated cash flows, and records any impairment expenses in the Consolidated Statements of Comprehensive (Loss) Income. If the Company incurs additional costs to renew or extend the life of an intangible asset, such costs are added to the remaining unamortized cost of the asset, if any, and the sum is amortized over the extended remaining life of the asset.

Goodwill is tested for impairment annually or more frequently if changes in circumstances or the occurrence of events suggest that impairment may exist. The Company uses widely accepted valuation techniques to determine the fair value of its

[19]

reporting units used in its annual goodwill impairment analysis. The Company’s valuation is primarily based on qualitative and quantitative assessments regarding the fair value of the reporting unit relative to its carrying value. The Company also models the fair value of the reporting unit based on projected earnings and cash flows of the reporting unit. The Company performed a qualitative assessment of goodwill and did not identify any indicators of impairment during the quarter.

IPR&D intangible assets represent the value assigned to acquired R&D projects that principally represent rights to develop and sell a product that the Company has acquired which have not yet been completed or approved. These assets are subject to impairment testing until completion or abandonment of each project. Impairment testing requires the development of significant estimates and assumptions involving the determination of estimated net cash flows for each quarter for each project or product (including net revenue, cost of sales, R&D costs, selling and marketing costs and other costs which may be allocated), the appropriate discount rate to select in order to measure the risk inherent in each future cash flow stream, the assessment of each asset’s life cycle, the potential regulatory and commercial success risks, and competitive trends impacting the asset and each cash flow stream as well as other factors. The major risks and uncertainties associated with the timely and successful completion of the IPR&D projects include legal risk, market risk and regulatory risk. If applicable, upon abandonment of the IPR&D product, the assets are impaired.

During the three month period ended June 30, 2018, seven IPR&D projects were impaired primarily due to the anticipated market conditions and competition upon launch, resulting in impairment expenses of $61.6 million, while during the three month period ended June 30, 2017, the Company recognized impairment expense of $3.2 million for one product primarily due to market conditions upon launch. Additionally, during the three month period ended June 30, 2018, three product licensing rights were impaired due to market conditions, resulting in impairment expenses of $2.9 million; of which, $1.3 million was recorded to R&D expenses, compared to impairments of $4.7 million on two product licensing rights during the comparative prior year period.

During the six month period ended June 30, 2018, ten IPR&D projects were impaired primarily due to anticipated market conditions and competition upon launch, resulting in impairment expenses of $79.5 million, while in the comparative prior year period, the Company recognized impairment expenses of $3.4 million for three products primarily due to market conditions upon launch. Additionally, during the six month period ended June 30, 2018, five product licensing rights were impaired due to market conditions resulting in impairment expenses of $3.9 million; of which, $1.8 million was recorded to R&D expenses, compared to impairments of $4.7 million on two product licensing rights during the comparative prior year period.

The following table provides a summary of the activity in goodwill by segment for the six month period ended June 30, 2018 (in thousands):



	Consumer Health		Prescription Pharmaceuticals			Total
Balances at December 31, 2017	$	16,717	$	268,593		$	285,310
Currency translation adjustments	—		(1,195		)	(1,195		)
Acquisitions	—		—			—
Impairments	—		—			—
Dispositions	—		—			—
Balances at June 30, 2018	$	16,717	$	267,398		$	284,115

The following table sets forth the major categories of the Company’s intangible assets as of June 30, 2018 and December 31, 2017, and the weighted average remaining amortization period as of June 30, 2018 and December 31, 2017 (dollar amounts in thousands):

[20]



	Gross Amount		Accumulated Amortization			Reclass-ifications			Gross Impairment			Net Balance		Wtd Avg Remaining Amortization Period (years)
June 30, 2018
Product licensing rights	$	607,939	$	(229,970	)	$	5,300		$	(4,375	)	$	378,894	9.0
IPR&D	149,161		—			(5,300		)	(79,473		)	64,388		N/A - Indefinite lived
Trademarks	16,000		(5,840		)	—			—			10,160		17.6
Customer relationships	4,225		(2,188		)	—			—			2,037		7.8
Other intangibles	11,235		(6,902		)	—			—			4,333		5.7
	$	788,560	$	(244,900	)	$	—		$	(83,848	)	$	459,812
December 31, 2017
Product licensing rights	$	747,106	$	(205,549	)	$	—		$	(139,217	)	$	402,340	9.8
IPR&D	173,757		—			—			(24,596		)	149,161		N/A - Indefinite lived
Trademarks	16,000		(5,376		)	—			—			10,624		17.8
Customer relationships	4,225		(2,058		)	—			—			2,167		8.3
Other intangibles	11,235		(6,043		)	—			—			5,192		5.7
	$	952,323	$	(219,026	)	$	—		$	(163,813	)	$	569,484

Note 8 — Financing Arrangements

Term Loans

During 2014, in order to finance its acquisitions of Hi-Tech Pharmacal Co Inc. and VersaPharm Inc., the Company entered into two term loan agreements (the “Term Loans”) with certain lenders and with JPMorgan Chase Bank, N.A., as administrative agent. The aggregate principal amount financed was $1,045.0 million. As of June 30, 2018, outstanding debt under the Term Loans was $831.9 million and the Company was in full compliance with all applicable covenants which included customary limitations on indebtedness, distributions, liens, acquisitions, investments, and other activities. The Term Loans are scheduled to mature in 2021.

During the three and six month periods ended June 30, 2018, the Company amortized $1.3 million and $2.5 million, respectively of the deferred financing cost related to the Term Loans, resulting in $14.0 million remaining balance of deferred financing costs at June 30, 2018. The Company will amortize this balance using the straight-line method over the life of the Term Loan Agreements.

Subsequent to November 13, 2015, interest accrues based at the Company’s election, on an adjusted prime/federal funds rate (“ABR Loan”) or an adjusted LIBOR (“Eurodollar Loan”) rate, plus a margin of 4.00% for ABR Loans, and 5.00% for Eurodollar Loans. As of the date of the filing of this Form 10-Q until the maturity of the Term Loans, the Company's spread will be based upon the Ratings Level applicable on such date as documented below. As of June 30, 2018, the Company was a Ratings Level II for the Existing Term Loan Facility.



Ratings Level	Index Ratings (Moody’s/S&P)	Eurodollar Spread	ABR Spread
Level I	B1/B+ or higher	4.25%	3.25%
Level II	B2/B	4.75%	3.75%
Level III	B3/B- or lower	5.50%	4.50%

For the three month periods ended June 30, 2018 and 2017, the Company recorded interest expense of $13.6 million and $11.1 million, respectively, in relation to the Term Loans, while for the six month periods ended June 30, 2018 and 2017, the Company recorded interest expense of $25.9 million and $22.0 million, respectively in relation to the Term Loans.

JPMorgan Credit Facility

[21]

On April 17, 2014, the Akorn Loan Parties entered into a Credit Agreement (the “JPM Credit Agreement”) with JPMorgan as administrative agent, and Bank of America, N.A., as syndication agent for certain other lenders (at closing, Bank of America, N.A. and Wells Fargo Bank, N. A.) for a $150.0 million revolving credit facility (the “JPM Revolving Facility”).

As of June 30, 2018, the Company was in full compliance with all covenants applicable to the JPM Revolving Facility.

The Company may use any proceeds from borrowings under the JPM Revolving Facility for working capital needs and for the general corporate purposes of the Company and its subsidiaries. At June 30, 2018, there were no outstanding borrowings under the JPM Revolving Facility, and availability was $135.0 million.

The JPM Credit Agreement places customary limitations on indebtedness, distributions, liens, acquisitions, investments, and other activities of the Akorn Loan Parties in a manner designed to protect the collateral while providing flexibility for growth and the historic business activities of the Company and its subsidiaries.

Debt Maturities Schedule

Aggregate cumulative maturities of long-term obligations (including the Term Loans and the JPM Revolving Facility) as of June 30, 2018 are:



(In thousands)	2018		2019		2020		2021
Maturities of debt	$	—	$	—	$	—	$	831,938

Note 9 — (Loss) Earnings Per Share

Basic net (loss) income per common share is based upon the weighted average number of common shares outstanding during the period. Diluted net (loss) income per common share is based upon the weighted average number of common shares outstanding, including the dilutive effect, if any, of potentially dilutive securities using the treasury stock method.

The Company’s potentially dilutive shares consist of: (i) vested and unvested stock options that are in-the-money, and (ii) unvested RSUs.

A reconciliation of the (loss) earnings per share data from a basic to a fully diluted basis is detailed below (amounts in thousands, except per share data):



	Three Months Ended June 30,					Six Months Ended June 30,
	2018			2017		2018			2017
Net (loss) income	$	(87,984	)	$	2,537	$	(116,731	)	$	43,564
Net (loss) income per share:
Basic	$	(0.70	)	$	0.02	$	(0.93	)	$	0.35
Diluted	$	(0.70	)	$	0.02	$	(0.93	)	$	0.35
Shares used in computing net (loss) income per share:
Weighted average basic shares outstanding	125,332			124,660		125,286			124,541
Dilutive securities:
Stock option and unvested RSUs	—			534		—			314
Total dilutive securities	—			534		—			314
Weighted average diluted shares outstanding	125,332			125,194		125,286			124,855

Shares subject to stock options omitted from the calculation of (loss) income per share as their effect would have been anti-dilutive	3,842			2,268		3,815			3,991

Note 10 — Segment Information

[22]

During the three and six month periods ended June 30, 2018 and 2017, the Company reported results for the following two reportable segments:

- Prescription Pharmaceuticals

- Consumer Health

The Company’s Prescription Pharmaceuticals segment principally consists of generic and branded prescription pharmaceuticals products which span a broad range of indications as well as a variety of dosage forms including: sterile ophthalmics, injectables and inhalants, and non-sterile oral liquids, topicals and nasal sprays. The Company’s Consumer Health segment principally consists of animal health and OTC products, both branded and private label. OTC products include, but are not limited to, a suite of products for the treatment of dry eye sold under the TheraTears^® brand name.

Financial information about the Company’s reportable segments is based upon internal financial reports that aggregate certain operating information. The Company’s Chief Operating Decision Maker (“CODM”), as defined in ASC 280 - Segment Reporting, who is also the CEO, oversees operational assessments and resource allocations based upon the results of the Company’s reportable segments, which have available and discrete financial information.

Selected financial information by reportable segment is presented below (in thousands):



	Three Months Ended June 30,						Six Months Ended June 30,
	2018			2017			2018			2017
Revenues, net:
Prescription Pharmaceuticals	$	172,163		$	182,645		$	336,464		$	420,024
Consumer Health	18,781			16,495			38,543			32,536
Total revenues, net	190,944			199,140			375,007			452,560

Gross Profit:
Prescription Pharmaceuticals	73,286			95,906			146,794			236,862
Consumer Health	7,993			6,863			16,713			14,676
Total gross profit	81,279			102,769			163,507			251,538

Operating expenses	172,845			88,495			280,488			162,851

Operating (loss) income	(91,566		)	14,274			(116,981		)	88,687
Other expenses, net	(12,690		)	(7,524		)	(23,302		)	(16,611		)

(Loss) Income before income taxes	$	(104,256	)	$	6,750		$	(140,283	)	$	72,076

The Company manages its business segments to the gross profit level and manages its operating and other costs on a company-wide basis. Inter-segment activity at the gross profit level is minimal. The Company does not have discrete assets by segment, as certain manufacturing and warehouse facilities support more than one segment, and therefore does not report assets by segment. Financial information including revenues and gross profit from external customers by product or product line is not provided as to do so would be impracticable.

[23]

The following table sets forth the Company’s net revenues by geographic region for the three and six month periods ended June 30, 2018 and 2017. The Domestic region represents sales within the United States of America and its territories while the Foreign region represents sales within all other countries and territories (dollar amounts in thousands):



	Three Months Ended June 30, 2018			Three Months Ended June 30, 2017			Six Months Ended June 30, 2018			Six Months Ended June 30, 2017
Region	Amount		% of Total Revenues	Amount		% of Total Revenues	Amount		% of Total Revenues	Amount		% of Total Revenues
Domestic	$	186,726	97.8%	$	193,314	97.1%	$	367,740	98.1%	$	439,018	97.0%
Foreign	4,218		2.2%	5,826		2.9%	7,267		1.9%	13,542		3.0%
Total Revenues	$	190,944	100.0%	$	199,140	100.0%	$	375,007	100.0%	$	452,560	100.0%

Note 11 – Share Repurchases

In July 2016, the Company announced that the Board of Directors authorized a stock repurchase program (the "Stock Repurchase Program") pursuant to which the Company may repurchase up to $200.0 million of the Company’s common stock. The shares may be repurchased from time to time in open market transactions at prevailing market prices, in privately negotiated transactions or others, including accelerated stock repurchase arrangements, pursuant to a Rule 10b5-1 repurchase plan or by other means in accordance with federal securities laws. The timing and the amount of any repurchases will be determined by the Company’s management based on its evaluation of market conditions, capital allocation alternatives, and other factors. There is no guarantee as to the number of shares that will be repurchased, and the repurchase program may be suspended or discontinued at any time without notice and at the Company's discretion, and at this time no estimate to the effect on the results of the Company due to the Stock Repurchase Program can be made.

The Company did not repurchase any shares during the six month period ended June 30, 2018. In aggregate, over the life of the Stock Repurchase Program, the Company repurchased 1.8 million shares at an average purchase price of $24.89. As of June 30, 2018, the Company had $155.0 million remaining under the repurchase authorization.

Companies incorporated under Louisiana law are subject to the Louisiana Business Corporation Act ("LBCA"). Provisions of the LBCA eliminate the concept of treasury stock and require that shares repurchased by a company are to be treated as authorized but unissued shares instead of treasury stock. As a result, all stock repurchases are presented as a reduction to issued and outstanding shares of common stock.

Note 12 — Commitments and Contingencies

The Company has entered into strategic business agreements for the development and marketing of finished dosage form pharmaceutical products with various pharmaceutical development companies.

Each strategic business agreement includes a future payment schedule for contingent milestone payments and in certain strategic business agreements, minimum royalty payments. The Company will be responsible for contingent milestone payments and minimum royalty payments to these strategic business partners based upon the occurrence of future events. Each strategic business agreement defines the triggering event of its future payment schedule, such as meeting product development progress timeline, successful product testing and validation, successful clinical studies, various FDA and other regulatory approvals and other factors as negotiated in each agreement. None of the contingent milestone payments or minimum royalty payments is individually material to the Company.

The Company is engaged in various supply agreements with third parties that obligate the Company to purchase various active pharmaceutical ingredients or finished products at contractual minimum levels. None of these agreements is individually or in aggregate material to the Company. Further, the Company does not believe at this time that any of the purchase obligations represent levels above that of normal business demands.

The table below summarizes contingent, potential milestone payments that would become due to strategic partners in the years 2018 and beyond, assuming all such contingencies occur (in thousands):

[24]



Year ending December 31,	Milestone Payments
2018	$	6,124
2019	8,314
2020	5,070
2021 and Beyond	950
Total	$	20,458

Legal Proceedings

The Company is a party to legal proceedings and potential claims arising in the ordinary course of our business. The amount, if any, of ultimate liability with respect to such matters cannot be determined, but despite the inherent uncertainties of litigation, management of the Company believes that the ultimate disposition of such proceedings and exposure will not have a material adverse impact on the financial condition, results of operations, or cash flows of the Company. Set forth below are material updates to other legal proceedings of the Company.

Shareholder and Derivative Litigation Related to the Merger

As previously disclosed, on May 2, 2017, a purported shareholder of the Company filed a complaint in a putative class and derivative action in the Circuit Court of Cook County, Illinois, County Department, Chancery Division, captioned Robert J. Shannon, Jr. v. Fresenius Kabi AG, et al., Case No. 2017-CH-06322. The Shannon Action sought, among other things, to enjoin the transactions contemplated by the merger agreement or, in the alternative, to recover monetary damages. On April 30, 2018, the Circuit Court of Cook County, Illinois, County Department, Chancery Division granted the voluntary dismissal without prejudice of the Shannon Action pursuant to the plaintiff’s motion for dismissal.

On March 8, 2018, a purported shareholder of the Company filed a putative class action complaint entitled Joshi Living Trust v. Akorn, Inc. et al., in the United States District Court for the Northern District of Illinois alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. The complaint names as defendants the Company, Chief Executive Officer Rajat Rai, Chief Financial Officer Duane Portwood and Chief Accounting Officer Randall Pollard. The complaint alleges that defendants made materially false or misleading statements and/or material omissions by failing to disclose sooner the existence of investigations into data integrity at the Company. The Complaint seeks, among other things, an award of damages, attorneys’ fees and expenses. The Company disputes these claims. On May 24, 2018, the Court ordered that the lead plaintiff file an amended complaint not later than September 5, 2018, that defendants respond to the amended complaint by November 5, 2018. On May 31, 2018, the Court issued an order appointing Gabelli & Co. Investment Advisors, Inc. and Gabelli Funds, LLC as lead plaintiffs pursuant to the Private Securities Litigation Reform Act (“PSLRA”), and approving their selection of lead counsel and liaison counsel. On June 14, 2018, lead plaintiffs filed a motion to lift the PSLRA stay of discovery. On June 22, 2018, the Company filed a memorandum in opposition to the motion to lift the PSLRA stay. On June 26, 2018, the Court denied the motion to lift the PSLRA stay, subject to entry of a preservation order.

Additional Litigation Related to the Merger

On April 22, 2018, Fresenius Kabi AG delivered to Akorn a letter purporting to terminate the Merger Agreement. On April 23, 2018, Akorn filed a verified complaint entitled Akorn, Inc. v. Fresenius Kabi AG, Quercus Acquisition, Inc. and Fresenius SE & Co. KGaA, in the Court of Chancery of the State of Delaware for breach of contract and declaratory judgment. The complaint alleges, among other things, that (i) the defendants anticipatorily breached their obligations under the Merger Agreement by repudiating their obligation to close the Merger, (ii) the defendants knowingly and intentionally breached their obligations under the Merger Agreement by working to slow the antitrust approval process and by engaging in a series of actions designed to hamper and ultimately block the Merger and (iii) Akorn has performed its obligations under the Merger Agreement, and is ready, willing and able to close the Merger. The complaint seeks, among other things, a declaration that Fresenius Kabi AG's termination is invalid, an order enjoining the defendants from terminating the Merger Agreement, and an order compelling the defendants to specifically perform their obligations under the Merger Agreement to use reasonable best efforts to consummate and make effective the Merger. On April 30, 2018, the defendants filed a verified counterclaim alleging that, due primarily to purported data integrity deficiencies at Akorn, the Company had breached representations and warranties and covenants in the Merger Agreement, and that it had experienced a material adverse effect. The verified counterclaim seeks, among other things, a declaration that defendants’ purported termination of the Merger Agreement was valid and that defendants are not obligated to consummate the transaction.

[25]

Other Matters

As previously disclosed in various reports filed with the SEC, on March 4, 2015, a purported class action complaint was filed entitled Yeung v. Akorn, Inc., et al., in the federal district court of Northern District of Illinois, No. 15-cv-1944. The complaint alleged that the Company and three of its officers violated the federal securities laws in connection with matters related to its accounting and financial reporting in the wake of its acquisitions of Hi-Tech Pharmaceutical Co., Inc. and VersaPharm, Inc. A second, related case entitled Sarzynski v. Akorn, Inc., et al., No. 15-cv-3921, was filed on May 4, 2015 making similar allegations. On August 24, 2015, the two cases were consolidated and a lead plaintiff appointed in In re Akorn, Inc. Securities Litigation. On July 5, 2016, the lead plaintiff group filed a consolidated amended complaint making similar allegations against the Company and an officer and former officer of the Company. The consolidated amended complaint seeks damages on behalf of the putative class. On August 9, 2016, the defendants filed a motion to dismiss the case. On March 6, 2017, the court denied the motion to dismiss and the defendants subsequently filed an answer to the consolidated amended complaint on March 27, 2017. On October 3, 2017, the parties informed the court that they had reached a settlement in principle of the litigation. In December 2017, following the court's order preliminarily approving the class plaintiffs’ proposed settlement for $24 million, the Company paid $5.0 million and its insurers paid $19.0 million. The court granted final approval of the settlement, reduced plaintiffs’ counsel’s request for attorney fees, and closed the case on June 5, 2018.

The Louisiana Attorney General filed suit, Number 624,522, State of Louisiana v. Abbott Laboratories, Inc., et al., in the Nineteenth Judicial District Court, Parish of East Baton Rouge, Louisiana state court, including Hi-Tech Pharmacal and other defendants. Louisiana’s complaint alleges that the defendants violated Louisiana state laws in connection with Medicaid reimbursement for certain vitamins, dietary supplements, and DESI products that were allegedly ineligible for reimbursement. The defendants filed exceptions of no cause of action and no right of action in response to Louisiana’s amended complaint resulting in a judgment entered on October 2, 2015, which dismissed all of Louisiana’s claims. Louisiana sought appellate review of the court’s decision. On October 21, 2016, the First Circuit Court of Appeal affirmed the trial court’s judgment in part, reversed it in part, and remanded the case for further proceedings. On December 22, 2016, the First Circuit denied Louisiana’s application for rehearing with respect to the First Circuit’s affirmance. On January 20, 2017, Louisiana filed an application for certiorari in the Louisiana Supreme Court as to the portion of the First Circuit’s decision affirming the trial court’s judgment. On January 23, 2017, the defendants filed an application for certiorari in the Louisiana Supreme Court as to the portion of the First Circuit’s decision reversing the trial court’s judgment. On March 13, 2017, the Louisiana Supreme Court denied both writ applications. On May 11, 2017, the defendants filed an exception of no cause of action in response to Louisiana’s amended complaint, which seeks the dismissal of Louisiana’s two remaining statutory claims. In a judgment entered on August 9, 2017, the trial court sustained defendants’ exception of no cause of action with respect to Louisiana’s claim under Louisiana’s Medicaid fraud statute. The trial court issued a further judgment on October 3, 2017, holding that for the one remaining claim, brought under Louisiana’s unfair trade practices claim, Louisiana could not seek civil penalties for conduct pre-dating June 2, 2006. The defendants filed an application for supervisory writs with the Court of Appeal for the First Circuit on October 24, 2017, seeking reversal of the trial court’s denial of their no cause of action exception with respect to the unfair trade practices claim, which would completely dismiss the case. After the defendants’ refiled the writ to cure a procedural defect, the First Circuit denied the writ on July 24, 2018.

The legal matters discussed above and others could result in losses, including damages, fines and civil penalties, and criminal charges, which could be substantial. We record accruals for these contingencies to the extent that we conclude that a loss is both probable and reasonably estimable. Given the nature of the litigation and investigations and the complexities involved, the Company is unable to reasonably estimate a possible loss for such matters until the Company knows, among other factors, (i) what claims, if any, will survive dispositive motion practice, (ii) the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii) how the discovery process will affect the litigation, (iv) the settlement posture of the other parties to the litigation and (v) any other factors that may have a material effect on the litigation or investigation. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on our results of operations in the period in which the amounts are accrued and/or our cash flows in the period in which the amounts are paid.

Data Integrity Investigations

[26]

As previously disclosed in various reports filed with the SEC, the Company and Fresenius Kabi AG, with the assistance of outside consultants, have been investigating alleged breaches of FDA data integrity requirements relating to product development at the Company. The Company has informed the FDA regarding the investigations and will continue to update the FDA as they proceed. Although Fresenius has sought to rely on purported data integrity deficiencies at Akorn as a basis to terminate the Merger Agreement, to date, the Company’s investigation has not found any facts that would result in a material impact on Akorn’s operations and the Company does not believe such investigations should affect the closing of the transaction with Fresenius.

Note 13 — Customer, Supplier and Product Concentration

Customer Concentration

In the three and six month periods ended June 30, 2018 and 2017, a significant portion of the Company’s gross and net revenues reported were to three large wholesale drug distributors, and a significant portion of the Company’s accounts receivable as of June 30, 2018 and December 31, 2017 were due from these wholesale drug distributors as well. AmerisourceBergen Health Corporation (“Amerisource”), Cardinal Health, Inc. (“Cardinal”) and McKesson Drug Company (“McKesson”) collectively referred to herein as the “Big 3 Wholesalers”, are all distributors of the Company’s products, as well as suppliers of a broad range of health care products. Aside from these three wholesale drug distributors, no other individual customer accounted for 10% or more of gross sales, net revenue or gross trade receivables for the indicated dates and periods. If sales to the Big 3 Wholesalers were to diminish or cease, the Company believes that the end users of its products would find little difficulty obtaining the Company’s products from another distributor. Further, the Company is subject to credit risk from its accounts receivable, more heavily weighted to the Big 3 Wholesalers, but as of and for the three and six month periods ended June 30, 2018 and 2017, the Company has not experienced significant losses with respect to its collection of these gross accounts receivable balances.

The following table sets forth the percentage of the Company's gross accounts receivable attributable to the Big 3 Wholesalers as of June 30, 2018 and December 31, 2017:



Big 3 Wholesalers combined:	June 30, 2018	December 31, 2017
Percentage of gross trade accounts receivable	87%	86%

The following table sets forth the percentage of the Company’s gross sales attributable to the Big 3 Wholesalers for the three and six month periods ended June 30, 2018 and 2017:



	Three Months Ended June 30,		Six Months Ended June 30,
Big 3 Wholesalers combined:	2018	2017	2018	2017
Percentage of gross sales	83%	81%	83%	80%

[27]

The following table sets forth the Company’s net revenues disaggregated by major customers for the three and six month periods ended June 30, 2018 and 2017 (dollar amounts in thousands):



	Three Months Ended June 30, 2018			Three Months Ended June 30, 2017			Six Months Ended June 30, 2018			Six Months Ended June 30, 2017
Disaggregation of net revenues by major customers	Amount		% of Total Revenues	Amount		% of Total Revenues	Amount		% of Total Revenues	Amount		% of Total Revenues
Amerisource	$	39,256	20.6%	$	39,654	19.9%	$	77,211	20.6%	$	83,591	18.5%
Cardinal	29,861		15.6%	33,260		16.7%	57,051		15.2%	82,228		18.2%
McKesson	43,128		22.6%	50,749		25.5%	96,349		25.7%	120,460		26.6%
Big 3 Wholesalers combined	112,245		58.8%	123,663		62.1%	230,611		61.5%	286,279		63.3%
All Others	78,699		41.2%	75,477		37.9%	144,396		38.5%	166,281		36.7%
Total Revenues	190,944		100.0%	199,140		100.0%	375,007		100.0%	452,560		100.0%

Sales to the Big 3 Wholesalers primarily represent purchases of products in the Prescription Pharmaceuticals segment and generate the majority of the Prescription Pharmaceuticals segment revenue. The Prescription Pharmaceuticals segment revenue represents 90.2% and 91.7% of the consolidated net revenue for three month periods ended June 30, 2018 and 2017, respectively, while during six month periods ended June 30, 2018 and 2017, the Prescription Pharmaceuticals segment revenue represents 89.7% and 92.8% of the consolidated net revenue, respectively. Chain pharmacies are the major customers in the Consumer Health segment. For more information, see Note 10 — Segment Information.

Supplier Concentration

The Company requires a supply of quality raw materials and components to manufacture and package pharmaceutical products for its own use and for third parties with which it has contracted. The principal components of the Company’s products are active and inactive pharmaceutical ingredients and certain packaging materials. Certain of these ingredients and components are available from only a single source and, in the case of certain of the Company’s abbreviated new drug applications and new drug applications, only one supplier of raw materials has been identified. Because FDA approval of drugs requires manufacturers to specify their proposed suppliers of active ingredients and certain packaging materials in their applications, FDA approval of any new supplier would be required if active ingredients or such packaging materials were no longer available from the specified supplier. The qualification of a new supplier could delay the Company’s development and marketing efforts. In addition, certain of the pharmaceutical products marketed by the Company are manufactured by a third party manufacturer, which serves as the Company’s sole source of that finished product. If for any reason the Company is unable to obtain sufficient quantities of any of the raw materials or components required to produce and package its products, it may not be able to manufacture its products as planned, which could have a material adverse effect on the Company’s business, financial condition and results of operations. Likewise, if the Company’s manufacturing partners experience any similar difficulties in obtaining raw materials or in manufacturing the finished product, the Company’s results of operations would be negatively impacted.

No individual supplier represented 10% or more of the Company’s purchases in the three and six month periods ended June 30, 2018 or 2017.

Product Concentration

In the three and six month periods ended June 30, 2018, none of the Company's products represented 10% or more of its total net revenue. In the three month period ended June 30, 2017, none of the Company's products represented 10% or more of its total net revenue, while Ephedrine Sulfate Injection represented approximately 13% of the Company's total net revenue in the six month period ended June 30, 2017. The Company attempts to minimize the risk associated with product concentrations by continuing to acquire and develop new products to add to its existing portfolio.

Note 14 — Income Taxes

On December 22, 2017, the Tax Cuts and Jobs Act (the “Tax Act”) was enacted and implements comprehensive tax legislation which, among other changes, reduces the federal statutory corporate tax rate from 35% to 21%, requires companies

[28]

to pay a one-time transition tax on earnings of certain foreign subsidiaries that were previously deferred, creates new provisions related to foreign sourced earnings, eliminates the domestic manufacturing deduction and moves to a territorial system. Additionally, in December 2017, the Securities and Exchange Commission staff issued Staff Accounting Bulletin No. 118 (“SAB 118”), which addresses how a company recognizes provisional amounts when a company does not have the necessary information available, prepared or analyzed (including computations) in reasonable detail to complete its accounting for the effect of the changes in the Tax Act. The measurement period, as defined in SAB 118, ends when a company has obtained, prepared and analyzed the information necessary to finalize its accounting, but cannot extend beyond one year. During the measurement period, provisional amounts may also be adjusted for the effects, if any, of interpretative guidance issued after December 31, 2017, by U.S. regulatory and standard-setting bodies.

Based on the provisions of the Tax Act, the Company re-measured its U.S. deferred tax assets and liabilities and adjusted its deferred tax balances to reflect the lower U.S. corporate income tax rate at December 31, 2017. The re-measurement of the Company's U.S. deferred tax assets and liabilities at the lower enacted U.S. corporate tax rate resulted in an income tax benefit of $26.9 million which was included as a discrete item in the 2017 income tax benefit. The Company’s foreign subsidiaries do not have accumulated earnings that can be distributed; therefore, the provisions of the Act related to the repatriation of foreign earnings are not applicable to the Company at December 31, 2017. No additional re-measurement adjustments have been made since December 31, 2017.

The following table sets forth information about the Company’s income tax (benefit) provision for the periods indicated (dollar amounts in thousands):



	Three Months Ended June 30,						Six Months Ended June 30,
	2018			2017			2018			2017
(Loss) Income before income taxes	$	(104,256	)	$	6,750		$	(140,283	)	$	72,076
Income tax (benefit) provision	(16,272		)	4,213			(23,552		)	28,512
Net (loss) income	$	(87,984	)	$	2,537		$	(116,731	)	$	43,564

Income tax (benefit) provision as a percentage of (loss) income before income taxes	15.6		%	62.4		%	16.8		%	39.6		%

During the three and six month periods ended June 30, 2018, the Company recorded an income tax benefit of $16.3 million and $23.6 million, or 15.6% and 16.8%, of (loss) before income tax in the applicable periods, respectively, while during the three and six month periods ended June 30, 2017, the Company recorded an income tax provision of $4.2 million and $28.5 million, or 62.4% and 39.6% of income before income tax in the applicable periods, respectively. The decreases in the income tax rate as a percentage of (loss) income before income tax for the three and six month periods ended June 30, 2018 as compared to the same periods in 2017, were principally the result of the enactment of the Tax Act in December 2017, and the incurrence of non-deductible fees in connection with the Delaware Action. The Company used the discrete method to calculate the quarterly provision.

As of June 30, 2018, the Company could not conclude that it was more likely than not that tax benefits from certain foreign net operating losses would be realized. Accordingly, as of the six month period ended June 30, 2018, the Company increased its valuation allowance to $11.9 million for certain of the losses at its Indian subsidiary and the entire amount of the loss at its Swiss subsidiary, compared to a valuation allowance of $10.5 million as of December 31, 2017.

In accordance with ASC 740-10-25, Income Taxes - Recognition, the Company reviews its tax positions to determine whether it is “more likely than not” that its tax positions will be sustained upon examination, and if any tax positions are deemed to fall short of that standard, the Company establishes reserves based on the financial exposure and the likelihood that its tax positions would not be sustained. Based on its evaluations, the Company determined that it would not recognize tax benefits on $25.5 million related to uncertain tax positions as of June 30, 2018. If recognized, $2.9 million of the above positions will impact the Company’s effective rate, while the remaining $22.6 million would result in adjustments to the Company’s deferred taxes. The Company accounts for interest and penalties as income tax expense. During the six month period ended June 30, 2018, the Company recorded no penalties and $0.7 million interest related to unrecognized tax benefits. As of June 30, 2018, the Company had an accrual balance of $8.9 million and $6.7 million of penalties and interest, respectively.

Note 15 – Related Party Transactions

[29]

In 2018 and 2017, the Company obtained legal services from Polsinelli PC, a law firm for which the spouse of the Company’s Executive Vice President, General Counsel and Secretary is an attorney and shareholder. During the three month periods ended June 30, 2018 and 2017, the Company obtained legal services totaling $1.1 million and $0.2 million, respectively. During the six months period ending, June 30, 2018 and 2017, the Company obtained legal services totaling $1.7 million and $0.6 million, of which $1.1 million and $0.3 million was payable as of June 30, 2018 and 2017, respectively.

During the three month periods ended June 30, 2018 and 2017, the Company also obtained and paid legal services totaling $0.2 million and $0.1 million, respectively, to Segal McCambridge Singer & Mahoney, a firm for which the brother in law of the Company's Executive Vice President, General Counsel and Secretary is a partner, and during the six months period ending, June 30, 2018 and 2017, the Company obtained and paid legal services totaling $0.4 million and $0.3 million to the same firm.

Note 16 – Recently Issued and Adopted Accounting Pronouncements

Recently Issued Accounting Pronouncements

In June 2018, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") No. 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. The amendments in this Update expand the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. Under this ASU, an entity should apply the requirements of Topic 718 to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost (that is, the period of time over which share-based payment awards vest and the pattern of cost recognition over that period). The amendments specify that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The amendments also clarify that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606, Revenue from Contracts with Customers. The amendments in this ASU are effective for public entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606. The Company believes that the adoption of this ASU will not have a material impact on its financial position, results of operations or cash flows.

In February 2016, FASB issued ASU No. 2016-02 - Leases, which establishes a comprehensive new lease accounting model. The new standard clarifies the definition of a lease and causes lessees to recognize leases on the balance sheet as a lease liability with a corresponding right-of-use asset for leases with a lease term of more than one year. ASU 2016-02 is effective for financial statements issued for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The new standard requires a modified retrospective transition for capital or operating leases existing at or entered into after the beginning of the earliest comparative period presented in the financial statements, but it does not require transition accounting for leases that expire prior to the date of initial application. Upon adoption, operating leases will be reported on the statement of financial position as gross-up assets and liabilities. The Company has begun evaluating and planning for adoption and implementation of this ASU, including reviewing all material leases, the ASU practical expedient guidelines, current accounting policy elections, and assessing the overall financial statement impact. We expect this ASU will have a material impact on the Company’s financial position. The impact on the Company’s results of operations is currently being evaluated. The impact of this ASU is non-cash in nature and is not expected to affect the Company’s cash flows.

Recently Adopted Accounting Pronouncements

In May 2017, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") No. 2017-09, Compensation — Stock Compensation (Topic 718): Scope of Modification Accounting, which provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. Per the ASU, an entity should account for the effects of a modification unless all the following are met: (1) The fair value (or calculated value or intrinsic value, if such an alternative measurement method is used) of the modified award is the same as the fair value (or calculated value or intrinsic value, if such an alternative measurement method is used) of the original award immediately before the original award is modified. If the modification does not affect any of the inputs to the valuation technique that the entity uses to value the award, the entity is not required to estimate the value immediately before and after the modification, (2) The vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified, and (3) The classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. The current disclosure requirements in Topic 718 apply regardless of whether an entity is

[30]

required to apply modification accounting under the amendments in this ASU. The ASU is effective for public business entities for annual and interim periods in fiscal years beginning after December 15, 2017. Early adoption is permitted, including adoption in any interim period, for (1) public business entities for reporting periods for which financial statements have not yet been issued and (2) all other entities for reporting periods for which financial statements have not yet been made available for issuance. The amendments in this ASU should be applied prospectively to an award modified on or after the adoption date. The standard was adopted on January 1, 2018, and did not have a material impact on the Company's consolidated financial statements or financial statement disclosures.

In March 2017, the FASB issued ASU No. 2017-07, — Compensation — Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost, which apply to all employers, including not-for-profit entities, that offer to their employees defined benefit pension plans, other postretirement benefit plans, or other types of benefits accounted for under Topic 715. The amendments in this ASU require that an employer report the service cost component in the same line item or items as other compensation costs arising from services rendered by the pertinent employees during the period. The other components of net benefit cost as defined in paragraphs 715-30-35-4 and 715-60- 35-9 are required to be presented in the income statement separately from the service cost component and outside a subtotal of income from operations, if one is presented. If a separate line item or items are used to present the other components of net benefit cost, that line item or items must be appropriately described. If a separate line item or items are not used, the line item or items used in the income statement to present the other components of net benefit cost must be disclosed. The amendments in this ASU also allow only the service cost component to be eligible for capitalization when applicable (for example, as a cost of internally manufactured inventory or a self-constructed asset). The amendments in this ASU are effective for public business entities for annual periods beginning after December 15, 2017, including interim periods within those 3 annual periods. Disclosures of the nature of and reason for the change in accounting principle are required in the first interim and annual periods of adoption. The amendments in this ASU should be applied retrospectively for the presentation of the service cost component and the other components of net periodic pension cost and net periodic postretirement benefit cost in the income statement and prospectively, on and after the effective date, for the capitalization of the service cost component of net periodic pension cost and net periodic postretirement benefit in assets. The amendments allow a practical expedient that permits an employer to use the amounts disclosed in its pension and other postretirement benefit plan note for the prior comparative periods as the estimation basis for applying the retrospective presentation requirements. Disclosure that the practical expedient was used is required. The standard was adopted on January 1, 2018, and did not have a material impact on the Company's consolidated financial statements or financial statement disclosures.

In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash (a consensus of the FASB Emerging Issues Task Force), which addresses classification and presentation of changes in restricted cash on the statement of cash flows. The standard requires an entity’s reconciliation of the beginning-of-period and end-of-period total amounts shown on the statement of cash flows to include in cash and cash equivalents amounts generally described as restricted cash and restricted cash equivalents. The ASU does not define restricted cash or restricted cash equivalents, but an entity will need to disclose the nature of the restrictions. The ASU is effective for public business entities for annual and interim periods in fiscal years beginning after December 15, 2017. For all other entities, the ASU is effective for fiscal years beginning after December 15, 2018, and interim periods in fiscal years beginning after December 15, 2019. Early adoption is permitted, including adoption in an interim period. If an entity early adopts the amendments in an interim period, adjustments should be reflected at the beginning of the fiscal year that includes that interim period. Entities should apply this ASU using a retrospective transition method to each period presented. The standard was adopted on January 1, 2018, and did not have a material impact on the Company's consolidated financial statements or financial statement disclosures.

In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments. This standard amends and adjusts how cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years and will require adoption on a retrospective basis unless impracticable. If impracticable the Company would be required to apply the amendments prospectively as of the earliest date possible. The standard was adopted on January 1, 2018, and did not have a material impact on the Company's consolidated financial statements or financial statement disclosures.

In May 2014, FASB issued ASU 2014-09 - Revenue from Contracts with Customers (Topic 606), as modified by subsequently issued ASUs 2015-14, 2016-08, 2016-10, 2016-12 and 2016-20 (collectively ASU 2014-09). ASU 2014-09 superseded the revenue recognition requirements in ASC (Topic 605) Revenue Recognition, and most industry specific guidance. This ASU also supersedes some cost guidance included in ASC 605-35 Revenue Recognition Construction Type and Production Type Contracts. Similar to the current guidance, the Company will need to make significant estimates related to variable consideration at the point of sale, including chargebacks, rebates, product returns, and other discounts and allowances. Revenue will be recognized at a point in time upon the transfer of control of the Company's products, which occurs upon

[31]

delivery for substantially all of the Company's sales. The Company has adopted the practical expedient to exclude all sales taxes and contract fulfillment costs from the transaction price. The Company adopted the standard effective January 1, 2018 using the modified retrospective approach. The adoption of ASU 2014-09 did not have a material impact on the Company’s consolidated financial position, results of operations, equity or cash flows as of the adoption date or for the three months ended March 31, 2018. See Note 13 — Customer, Supplier and Product Concentration for the disaggregation of net revenues by major customers.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

FORWARD-LOOKING STATEMENTS AND FACTORS AFFECTING FUTURE RESULTS

Certain statements in this Form 10-Q are forward-looking in nature and are intended to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” "will," “could,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of such terms or other comparable terminology. Any forward-looking statements, including statements regarding our intent, beliefs or expectations are not guarantees of future performance. These statements are subject to risks and uncertainties and actual results, levels of activity, performance or achievements may differ materially from those in the forward-looking statements as a result of various factors. See “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017, as filed with the SEC on February 28, 2018, in our Form 10-Q filed on May 2, 2018, and in this Form 10-Q, which include, but are not limited to, the following items:


•	There are material uncertainties and risks associated with the pending Merger Agreement and Merger


◦	The announcement and pendency of the Merger may impede Akorn’s ability to retain and hire key personnel, its ability to maintain relationships with its customers, suppliers and others with whom it does business, or its operating results and business generally


◦	The attention of our employees and management may be diverted due to activities related to the Merger, which may affect our business operations


◦	Matters relating to the Merger (including integration planning) may require substantial commitments of time and resources by Akorn management, which could harm our relationships with our employees, customers, distributors, suppliers or other business partners, and may result in a loss of or a substantial decrease in purchases by our customers


◦	The Merger Agreement restricts us from engaging in certain actions without the approval of Fresenius Kabi, which could prevent us from pursuing certain business opportunities outside the ordinary course of business that arise prior to the closing of the Merger


◦	Shareholder litigation in connection with the transactions contemplated by the Merger Agreement may result in significant costs of defense, indemnification and liability; and


◦	The outcome of the Company’s and Fresenius Kabi’s investigations into alleged breaches of FDA data integrity requirements relating to product development at the Company, and any actions taken by the Company, Fresenius Kabi, third parties or the FDA as a result of such investigations may result in significant costs


◦	The Fresenius Kabi AG’s purported termination of the Merger Agreement and the litigation related to the Merger pending in the Court of Chancery of the State of Delaware may result in significant costs and in the Merger not being completed in a timely manner or at all


•	The risk that the pending merger may not be completed in a timely manner or at all


•	Our growth depends on our ability to timely and efficiently develop and successfully launch and market new pharmaceutical products


•	We could experience business interruptions at our manufacturing facilities, which may have a material adverse effect on our business, financial position and results of operations

[32]


•	A significant portion of our revenues are generated through the sale of products manufactured by third parties, the loss or failure of any of which may have a material adverse effect on our business, financial position and results of operations


•	We depend on a small number of wholesalers to distribute our products, the loss of any of which could have a material adverse effect on our business


•	We may be subject to significant disruptions or failures in our information technology systems and network infrastructures that could have a material adverse effect on our business


•	We depend on our employees and must continue to attract and retain key personnel in order to compete successfully, and any failure to do so could hinder successful execution of our business and development plans and have a material adverse effect on our financial position and results of operation


•	Our inability to effectively manage or support our growth may have a material adverse effect on our business, financial position, results of operations and liquidity and could cause the price of our common stock to decline


•	We have entered into several strategic business alliances that may not result in marketable products and may have a material adverse effect on our business, financial position, results of operations and liquidity


•	We become involved in legal proceedings and governmental investigations from time to time, any of which may result in substantial losses, government enforcement actions, damage to our business and reputation and place a strain on our internal resources


•	Charges to earnings resulting from acquisitions could have a material adverse effect on our business, financial position and results of operations


•	Many of the raw materials and components used in our products come from a single source, the loss of any of which could have a material adverse effect on our business


•	Sales of our products may be adversely affected by the continuing consolidation of our customer base, which may have a material adverse effect on our business plans, financial position and results of operations


•	Our branded products may become subject to increased generic competition


•	We are subject to extensive government regulations which if they change and or we are not in compliance with, could increase our costs, subject us to various obligations and fines, or prevent us from selling our products or operating our facilities


•	Changes in healthcare law and policy changes may adversely affect our business plans and results of operations


•	The FDA may require us to stop marketing certain unapproved drugs (non-application drugs marketed prior to the 1962 Amendments of the FDC Act), which could have a material adverse effect on our business, financial position and results of operations


•	Failure to comply with the U.S. Foreign Corrupt Practices Act could subject us to, among other things, penalties and legal expenses that could harm our reputation and have a material adverse effect on our business, financial condition and operating results


•	Third parties may claim that we infringe on their proprietary rights and may prevent or delay us from manufacturing and selling some of our new products


•	We may need to obtain additional capital to continue to grow our business


•	Our indebtedness reduces our financial and operating flexibility


•	We may not generate cash flow sufficient to pay interest and make required principal repayments on our Term Loans

[33]

If any of these risks or uncertainties materialize, or if our underlying assumptions prove to be incorrect, actual results may vary significantly from what we projected or as compared to prior periods. As a result, you should not place undue reliance on any forward-looking statements. Any forward-looking statement you read in the following Management’s Discussion and Analysis of Financial Condition and Results of Operations reflects our current views with respect to future events and is subject to these and other risks, uncertainties, and assumptions relating to our operations, results of operations, growth strategy, and liquidity. Unless required by law, we undertake no obligation to publicly update any forward-looking statements for any reason, whether as a result of new information, future events, or otherwise.

[34]

RESULTS OF OPERATIONS

The following table sets forth the amounts and percentages of total revenue for certain items from our Condensed Consolidated Statements of Comprehensive (Loss) Income and our segment reporting information for the three and six months ended June 30, 2018 and 2017 (dollar amounts in thousands):



	Three Months Ended June 30,										Six Months Ended June 30,
	2018					2017					2018					2017
	Amount			% of Revenue		Amount			% of Revenue		Amount			% of Revenue		Amount			% of Revenue
Revenues, net:
Prescription Pharmaceuticals	$	172,163		90.2	%	$	182,645		91.7	%	$	336,464		89.7	%	$	420,024		92.8	%
Consumer Health	18,781			9.8	%	16,495			8.3	%	38,543			10.3	%	32,536			7.2	%
Total revenues, net	190,944			100.0	%	199,140			100.0	%	375,007			100.0	%	452,560			100.0	%
Gross profit:
Prescription Pharmaceuticals	73,286			42.6	%	95,906			52.5	%	146,794			43.6	%	236,862			56.4	%
Consumer Health	7,993			42.6	%	6,863			41.6	%	16,713			43.4	%	14,676			45.1	%
Total gross profit	81,279			42.6	%	102,769			51.6	%	163,507			43.6	%	251,538			55.6	%
Operating expenses:
SG&A expenses	83,694			43.8	%	53,981			27.1	%	146,677			39.1	%	101,564			22.4	%
Acquisition-related costs	64			—	%	76			—	%	75			—	%	87			—	%
R&D expenses	74,271			38.9	%	15,876			8.0	%	105,238			28.1	%	27,167			6.0	%
Amortization of intangible assets	13,182			6.9	%	15,504			7.8	%	26,372			7.0	%	30,975			6.8	%
Impairment of intangible assets	1,634			0.9	%	3,058			1.5	%	2,126			0.6	%	3,058			0.7	%
Operating (loss) income	$	(91,566	)	(48.0	)%	$	14,274		7.2	%	$	(116,981	)	(31.2	)%	$	88,687		19.6	%
Other expense, net	(12,690		)	(6.6	)%	(7,524		)	(3.8	)%	(23,302		)	(6.2	)%	(16,611		)	(3.7	)%
(Loss) Income before income taxes	(104,256		)	(54.6	)%	6,750			3.4	%	(140,283		)	(37.4	)%	72,076			15.9	%
Income tax provision	(16,272		)	(8.5	)%	4,213			2.1	%	(23,552		)	(6.3	)%	28,512			6.3	%
Net (loss) income	$	(87,984	)	(46.1	)%	$	2,537		1.3	%	$	(116,731	)	(31.1	)%	$	43,564		9.6	%

THREE MONTHS ENDED JUNE 30, 2018 COMPARED TO THREE MONTHS ENDED JUNE 30, 2017

Net revenue was $190.9 million for the three month period ended June 30, 2018, representing a decrease of $8.2 million, or 4.1%, as compared to net revenue of $199.1 million for the three month period ended June 30, 2017. The decrease in net revenue in the period was primarily due to $12.2 million decline in organic revenue that was partially offset by $5.9 million net revenue increase in new products and product relaunches. The $12.2 million decline in organic revenue was due to approximately $7.0 million, or 3.5%, and $5.2 million, or 2.6%, in price and volume declines, respectively. The organic revenue decline was principally due to the effect of competition on Nembutal and Ephedrine Sulfate Injection that were partially offset by revenue increase in Myorisan.

The Prescription Pharmaceuticals segment revenue of $172.2 million for the three month period ended June 30, 2018 represented a decrease of $10.5 million, or 5.7%, as compared to revenue of $182.6 million for the three month period ended June 30, 2017.

[35]

The Consumer Health segment revenue of $18.8 million for the three month period ended June 30, 2018 represented an increase of $2.3 million, or 13.9%, as compared to revenue of $16.5 million for three month period ended June 30, 2017. The $2.3 million increase in revenue is primarily attributed to the TheraTears® direct-to-consumer ("DTC") advertising campaign.

The net revenue for the three month period ended June 30, 2018 of $190.9 million was net of adjustments totaling $316.9 million for chargebacks, rebates, administrative fees and others, product returns, discounts and allowances and advertising, promotions and other. Chargeback expenses for the three month period ended June 30, 2018 were $222.5 million, or 43.8% of gross sales, compared to $237.3 million, or 41.8% of gross sales for the three month period ended June 30, 2017. The $14.8 million decrease in chargeback expense was due to lower gross sales in the current period as compared to prior year same period. Rebates, administrative fees and other expenses for the three month period ended June 30, 2018 were $75.1 million, or 14.8% of gross sales, compared to $109.8 million, or 19.4% for three month period ended June 30, 2017. The $34.7 million decrease in rebates, administrative fees and other expenses was primarily due to volume declines as well as product mix and customer mix. Our product returns provision for the three month period ended June 30, 2018 was $6.1 million, or 1.2% of gross sales, compared to $8.1 million, or 1.4% of gross sales for the three month period ended June 30, 2017. Discounts and allowances were $9.9 million or 2.0% of gross sales for the three month period ended June 30, 2018, compared to $10.8 million, or 1.9% of gross sales for the three month period ended June 30, 2017. Advertisement and promotion expenses were $3.2 million or 0.6% of gross sales for the three month period ended June 30, 2018, compared to $2.0 million, or 0.4% of gross sales for the three month period ended June 30, 2017.

Consolidated gross profit for the quarter ended June 30, 2018 was $81.3 million, or 42.6% of net revenue, compared to $102.8 million, or 51.6% of net revenue, in the corresponding prior year quarter. The decline in the gross profit percentage was principally due to unfavorable product mix shifts primarily driven by the effect of competition on Ephedrine Sulfate Injection and Nembutal, as well as increased operating costs at our manufacturing facilities.

Total operating expenses were $172.8 million in the three month period ended June 30, 2018, an increase of $84.3 million, or 95.3%, from the prior year quarter amount of $88.5 million. The $84.3 million increase was primarily driven by approximately $58.4 million and $29.7 million increases in Research and development (“R&D”) expenses and Selling, general and administrative (“SG&A”), respectively that were partially offset by a decrease of $2.3 million in Amortization of intangibles. The following is a discussion of the main drivers of the increase:

R&D expenses were $74.3 million in the three month period ended June 30, 2018, an increase of $58.4 million or 367.8% over the prior year quarter amount of $15.9 million. The $58.4 million increase was primarily due to IPR&D impairments of $61.6 million in the three month period ended June 30, 2018 compared to IPR&D impairments of $3.2 million in the three month period ended June 30, 2017.

SG&A expenses were $83.7 million in the three month period ended June 30, 2018, an increase of $29.7 million, or 55.0%, from the prior year quarter amount of $54.0 million. The primary drivers of the $29.7 million increase were $23.7 million legal expenses attributed to the Delaware Action and $12.4 million expenses related to the data integrity assessment projects.

Non-operating expenses were $12.7 million in the three month period ended June 30, 2018, an increase of $5.2 million, or 68.7%, from the comparative prior year period amount of $7.5 million. The $5.2 million increase was primarily driven by $2.6 million income attributed to receipt and subsequent sale of the Nicox securities that the Company received as a milestone payment in the second quarter of 2017, and $1.7 million increase in interest expense during the three month period ended June 30, 2018 compared to the same period in 2017.

For the three month period ended June 30, 2018, we recorded an income tax benefit of approximately $16.3 million on our net loss before income taxes of $104.3 million, which represented an effective tax benefit rate of 15.6%. In the prior year quarter ended June 30, 2017, our income tax provision was $4.2 million based on an effective tax provision rate of 62.4%. The decrease in the income tax rate as a percentage of (loss) income before income tax for the quarter ended June 30, 2018 as compared to the same period in 2017, was principally the result of the enactment of the Tax Act in December 2017, and the incurrence of non-deductible fees in connection with the Delaware Action.

The Company reported a net loss of $88.0 million for the three month period ended June 30, 2018, or 46.1% of net revenue, compared to net income of $2.5 million for the three month period ended June 30, 2017, or 1.3% of net revenue.

SIX MONTHS ENDED JUNE 30, 2018 COMPARED TO SIX MONTHS ENDED JUNE 30, 2017

[36]

Net revenue was $375.0 million for the six month period ended June 30, 2018, representing a decrease of $77.6 million, or 17.1%, as compared to net revenue of $452.6 million for the six month period ended June 30, 2017. The decrease in net revenue in the period was primarily due to $84.1 million decline in organic revenue. The $84.1 million decline in organic revenue was due to approximately $46.9 million, or 10.4%, and $37.2 million, or 8.2%, in volume and price declines, respectively. The organic revenue decline was principally due to the effect of competition on Ephedrine Sulfate Injection, Nembutal and Lidocaine Ointment.

The Prescription Pharmaceuticals segment revenue of $336.5 million for the six month period ended June 30, 2018 represented a decrease of $83.6 million, or 19.9%, as compared to revenue of $420.0 million for the six month period ended June 30, 2017.

The Consumer Health segment revenue of $38.5 million for the six month period ended June 30, 2018 represented an increase of $6.0 million, or 18.5%, as compared to revenue of $32.5 million for the six month period ended June 30, 2017. The $6.0 million increase in revenue is primarily attributed to the TheraTears® direct-to-consumer ("DTC") advertising campaign.

The net revenue for the six month period ended June 30, 2018 of $375.0 million was net of adjustments totaling $653.3 million for chargebacks, rebates, administrative fees and others, product returns, discounts and allowances and advertising, promotions and other. Chargeback expenses for the six month period ended June 30, 2018 were $446.4 million, or 43.4% of gross sales, compared to $517.4 million, or 41.5% of gross sales for the six month period ended June 30, 2017. The $71.0 million decrease in chargeback expense was due to lower gross sales in the current period as compared to prior year same period. Rebates, administrative fees and other expenses for the six month period ended June 30, 2018 were $167.4 million, or 16.3% of gross sales, compared to $234.1 million, or 18.8% for six month period ended June 30, 2017. The $66.8 million decrease in rebates, administrative fees and other expenses was primarily due to volume declines as well as product mix and customer mix. Our product returns provision for the six month period ended June 30, 2018 was $13.3 million, or 1.3% of gross sales, compared to $16.5 million, or 1.3% of gross sales for the six month period ended June 30, 2017. Discounts and allowances were $20.2 million or 2.0% of gross sales for the six month period ended June 30, 2018, compared to $23.8 million, or 1.9% of gross sales for the six month period ended June 30, 2017. Advertisement and promotion expenses were $6.1 million or 0.6% of gross sales for the six month period ended June 30, 2018, compared to $3.2 million, or 0.3% of gross sales for the six month period ended June 30, 2017.

Consolidated gross profit for the six month period ended June 30, 2018 was $163.5 million, or 43.6% of net revenue, compared to $251.5 million, or 55.6% of net revenue, in the corresponding prior year period. The decline in the gross profit percentage was principally due to unfavorable product mix shifts primarily driven by the effect of competition on Ephedrine Sulfate Injection and Nembutal, as well as increased operating costs at our manufacturing facilities.

Total operating expenses were $280.5 million in the six month period ended June 30, 2018, an increase of $117.6 million, or 72.2%, from the comparative prior year period amount of $162.9 million. The $117.6 million increase was primarily driven by approximately $78.1 million and $45.1 million increases in Research and development (“R&D”) expenses and Selling, general and administrative (“SG&A”), respectively that were partially offset by a decrease of and $4.6 million in Amortization of intangibles. The following is a discussion of the main drivers of the increase:

R&D expenses were $105.2 million in the six month period ended June 30, 2018, an increase of $78.1 million or 287.4% over the comparative prior year period amount of $27.2 million. The $78.1 million increase was primarily due to IPR&D impairments of $79.5 million in the six month period ended June 30, 2018 compared to IPR&D impairments of $3.4 million in the six month period ended June 30, 2017.

SG&A expenses were $146.7 million in the six month period ended June 30, 2018, an increase of $45.1 million, or 44.4%, from the comparative prior year period amount of $101.6 million. The primary drivers of the $45.1 million increase were $25.0 million legal expenses attributed to the Delaware Action, $10.3 million increase in advertising and promotional expenses of which $9.5 million is related to the TheraTears® direct-to-consumer ("DTC") advertising campaign and $16.7 million expenses related to the data integrity assessment projects.

Non-operating expenses were $23.3 million in the six month period ended June 30, 2018, an increase of $6.7 million, or 40.3%, from the comparative prior year period amount of $16.6 million. The $6.7 million increase was primarily driven by $2.6 million income attributed to receipt and subsequent sale of the Nicox securities that the Company received as a milestone payment in the second quarter of 2017, and $1.7 million increase in interest expense during the six month period ended June 30, 2018 compared to the same period in 2017.

[37]

For the six month period ended June 30, 2018, we recorded an income tax benefit of approximately $23.6 million on our net loss before income taxes of $140.3 million, which represented an effective tax benefit rate of 16.8%. In the prior year six month period ended June 30, 2017, our income tax provision was $28.5 million based on an effective tax provision rate of 39.6%. The decrease in the income tax rate as a percentage of (loss) income before income tax for the six month period ended June 30, 2018 as compared to the same period in 2017, was principally the result of the enactment of the Tax Act in December 2017, and the incurrence of non-deductible fees in connection with the Delaware Action.

The Company reported a net loss of $116.7 million for the six month period ended June 30, 2018, or 31.1% of net revenue, compared to net income of $43.6 million for the six month period ended June 30, 2017, or 9.6% of net revenue.

FINANCIAL CONDITION AND LIQUIDITY

As of June 30, 2018, we had cash and cash equivalents of $296.8 million, which was $71.3 million less than our cash and cash equivalents balance of $368.1 million as of December 31, 2017. This decrease in cash and cash equivalents was driven by net investing cash outflows of $35.9 million, net operating cash outflows of $31.3 million, and net financing cash outflows of $4.5 million. Our net working capital was $524.5 million at June 30, 2018, compared to $559.1 million at December 31, 2017, a decrease of $34.5 million.

Operating Cash Flows



(amounts in thousands)	Six Months Ended June 30,
	2018			2017
OPERATING ACTIVITIES:
Consolidated net (loss) income	$	(116,731	)	$	43,564
Adjustments to reconcile consolidated net income to net cash (used in) provided by operating activities:
Depreciation and amortization	40,439			42,212
Amortization of debt financing costs	2,608			2,608
Impairment of intangible assets	83,349			8,079
Non-cash stock compensation expense	11,453			9,844
Income from available-for-sale securities	—			(3,032		)
Deferred income taxes, net	(24,512		)	(2,341		)
Loss on sale of available-for-sale securities	—			196
Other	481			(288		)
Changes in operating assets and liabilities:
Trade accounts receivable	(45,893		)	105,848
Inventories, net	(7,735		)	(6,225		)
Prepaid expenses and other current assets	8,176			2,078
Trade accounts payable	602			(13,465		)
Accrued expenses and other liabilities	16,490			(30,051		)
NET CASH (USED IN) PROVIDED BY OPERATING ACTIVITIES	$	(31,273	)	$	159,027

During the year to date period ended June 30, 2018, operating activities generated $31.3 million in negative cash flows. This negative cash flow was principally the result of our consolidated net loss of $116.7 million, an increase of $45.9 million in trade accounts receivable, an increase of $7.7 million in inventories, net, partially offset by a net inflow from non-cash expenses of $113.3 million, an increase of $16.5 million in accrued expenses and other liabilities, a decrease in prepaid expenses and other current assets of $8.2 million, and a $0.6 million increase in trade accounts payable.

During the six month period ended June 30, 2017, operating activities generated $159.0 million in cash flows. This positive cash flow was principally the result of a decrease of $105.8 million in accounts receivable, consolidated net income of $43.6 million, a $57.4 million net inflow of non-cash expenses, partially offset by a decrease of $30.1 million in accrued expenses and other liabilities and a $13.5 million trade payable.

[38]

Investing Cash Flows



(amounts in thousands)	Six Months Ended June 30,
	2018			2017
INVESTING ACTIVITIES:
Proceeds from disposal of assets	$	20		$	4,811
Payments for intangible assets	(50		)	(200		)
Purchases of property, plant and equipment	(35,862		)	(50,072		)
NET CASH USED IN INVESTING ACTIVITIES	$	(35,892	)	$	(45,461	)

We used $35.9 million in investing activities during the six month period ended June 30, 2018. Of this total, $35.9 million was used to acquire property, plant and equipment.

We used $45.5 million in investing activities during the six month period ended June 30, 2017. Of this total $50.1 million was used to acquire property, plant and equipment, partially offset by $4.8 million received in proceeds related to the disposition of assets.

Financing Cash Flows



(amounts in thousands)	Six Months Ended June 30,
	2018			2017
FINANCING ACTIVITIES:
Proceeds from the exercise of stock options	$	254		$	6,897
Payment of contingent acquisition liabilities	(4,793		)	—
Lease payments	(6		)	—
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES	$	(4,545	)	$	6,897

Financing activities used $4.5 million in the six month period ended June 30, 2018, consisting of $4.8 million used for consideration payable payments, partially offset by $0.3 million of proceeds from employee stock option exercises.

Financing activities provided $6.9 million in the six month period ended June 30, 2017, in proceeds from employee stock option exercises.

Liquidity and Capital Needs

We require certain capital resources in order to maintain and expand our business. Our future capital expenditures may include substantial projects undertaken to upgrade, expand and improve our manufacturing facilities, in the United States, India and Switzerland. Most notably, we continue to expend significant amounts in order to gain compliance with FDA requirements at AIPL. Furthermore, the Company expects to continue to expend significant amounts in order to comply with the DSCSA. We also expect to continue to incur a significant amount of expenses for the ongoing Delaware Action and data integrity related FDA compliance matters. Our cash obligations include the principal and interest payments due on our Term Loans and any amount we may borrow under the JPMorgan Facility (as both described throughout this report) and the amount required to effect the repurchase of shares of our common stock in accordance with the Stock Repurchase Program discussed in Item 1, Note 11 - "Share Repurchases." As of June 30, 2018, the Company had $155.0 million remaining under the repurchase authorization. We believe that our cash reserves, operating cash flows, and availability under our credit facilities will be sufficient to finance any future expansions and meet our cash needs for the foreseeable future.

Refer to Item 1, Note 8 - "Financing Arrangements" for further detail of debt obligations as of and for the quarter ended June 30, 2018.

CRITICAL ACCOUNTING POLICIES

The preparation of financial statements in accordance with generally accepted accounting principles requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. A summary of

[39]

our significant accounting policies is included in Part II - Item 8, Note 2 - "Summary of Significant Accounting Policies", in our Annual Report on Form 10-K for the year ended December 31, 2017 and in Item 1, Note 2 - "Summary of Significant Accounting Policies" of this Form 10-Q. Certain of our accounting policies are considered critical, as these policies require significant, difficult or complex judgments by management, often requiring the use of estimates about the effects of matters that are inherently uncertain.

The Company consolidates the financial statements of its foreign subsidiaries in accordance with ASC 830 - Foreign Currency Matters, under which the statement of operations amounts are translated from Indian rupees (“INR”) and Swiss Francs (“CHF”), respectively, to U.S. Dollars at the average exchange rate during the applicable period, while balance sheet amounts are generally translated at the exchange rate in effect as of the applicable balance sheet date. Cash flows are translated at the average exchange rate in place during the applicable period. Differences arising from foreign currency translation are included in accumulated other comprehensive loss and are carried as a separate component of equity on our condensed consolidated balance sheets.

OFF-BALANCE SHEET ARRANGEMENTS

We do not have any off-balance sheet arrangements that have had, or are reasonably likely to have, a current or future material effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources.

[40]

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

There has been no material change in the information reported under Part II, Item 7A - “Quantitative and Qualitative Disclosures About Market Risk” in our Form 10-K for the fiscal year ended December 31, 2017.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Our disclosure controls and procedures are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

As of June 30, 2018, an evaluation was conducted under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) of the Exchange Act). Based on this evaluation, such officers have concluded that our disclosure controls and procedures are effective as of June 30, 2018.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, for the three month period ended June 30, 2018 that have materially affected, or are reasonably likely to materially affect the Company’s internal control over financial reporting.

[41]

PART II. OTHER INFORMATION

Item 1. Legal Proceedings.

The Company’s disclosure of legal proceedings within Part I - Item 1, Note 12 - "Commitments and Contingencies" of this Report, is incorporated into this Part II - Item 1 by reference.

Item 1A. Risk Factors.

Other than the risk factors described in our Form 10-Q filed on May 2, 2018, and set forth below, there have been no material changes to the risk factors disclosed in Part 1 - Item 1A, of our Form 10-K for the year ended December 31, 2017:

We have filed a lawsuit against Fresenius Kabi AG, Quercus Acquisition, Inc. and Fresenius SE & Co. KGaA in relation to the Merger, and defendants filed a counterclaim. If we are unsuccessful in our lawsuit, our current shareholders may not realize the anticipated benefits contemplated by the Merger Agreement.

We believe that this lawsuit is necessary to enforce our rights under the Merger Agreement and to deliver to our shareholders the benefits of the Merger Agreement. At this stage, there is no way to predict the outcome of this lawsuit. If we are unsuccessful in our lawsuit, the Merger may not be consummated and our current shareholders may not receive the consideration which they are entitled, pursuant to the Merger Agreement, to receive upon consummation of the Merger.

[42]

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None.

Item 6. Exhibits.

The list of exhibits in the Exhibit Index to this Report is incorporated herein by reference.

[43]

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.



	AKORN, INC.

	/s/ DUANE A. PORTWOOD
	Duane A. Portwood
	Chief Financial Officer
	(on behalf of the registrant and as its Principal Financial Officer)

Date: August 1, 2018

[44]

EXHIBIT INDEX

Those exhibits marked with a (*) refer to exhibits filed herewith.



Exhibit No.		Description


31.1 *		Certification of Chief Executive Officer pursuant to Rule 13a-14(a).

31.2 *		Certification of Chief Financial Officer pursuant to Rule 13a-14(a).

32.1 *		Certification of Chief Executive Officer pursuant to 18 U.S.C. § 1350.

32.2 *		Certification of Chief Financial Officer pursuant to 18 U.S.C. § 1350.

101 *		The financial statements and footnotes from the Akorn, Inc. Quarterly Report on Form 10-Q for the three and six month periods ended June 30, 2018, filed on August 1, 2018, formatted in XBRL: (i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Comprehensive (Loss) Income, (iii) Condensed Consolidated Statement of Shareholders’ Equity, (iv) Condensed Consolidated Statements of Cash Flows, and (v) Notes to Condensed Consolidated Financial Statements.

[45]